

# PATRICK M. MORIARTY, MD, FACP, FACC, FNLA, FESC

**Division of Clinical Pharmacology**  
**University of Kansas Medical Center**  
**3901 Rainbow Blvd. Mail Stop 3008**  
**Kansas City, KS 66160**  
**Phone: (913) 588-4027**  
**Fax: (913) 588-4074**  
**E-mail: [PMoriart@kumc.edu](mailto:PMoriart@kumc.edu)**

## LICENSE & CERTIFICATIONS

**1994-present** Doctor of Medicine, Kansas State Board of Healing Arts  
License Number: KS 04-253618

**1989** Educational Commission for Foreign Medical Graduates

## EDUCATION

**1984** Doctor of Medicine and Surgery, University of Rome, Italy

**1977** Liceo Scientifico, Perugia, Italy

**1976** Bachelor of Arts, St. Michael's College, Winooski, VT.

## POST-GRADUATE TRAINING

**1995-1997** Clinical Pharmacology, University of Kansas Medical Center, Kansas City, KS

**1992-1994** Medical Residency, University of Kansas Medical Center, Kansas City, KS

**1991-1992** Internship in Medicine, University of Kansas Medical Center, Kansas City, KS

**1985-1989** International Clinical Labs, Drs. R. J. Moriarty & F. M. Mudawwar, Springfield, MA

**1984-1985** Clinical Rotations in Emergency Medicine, ENT, Urology, Anesthesia, Internal Medicine and Critical Care Unit, Berkshire Medical Center, University of Massachusetts, Pittsfield, MA.

**1983** Berkshire Medical Center, University of Massachusetts, Nephrology, Pulmonary and Internal Medicine, Pittsfield, MA,

- 1981** St. Luke's/Roosevelt Hospital, Infectious Disease, New York, NY
- 1979** Berkshire Medical Center, University of Massachusetts, Pathology, Pittsfield, MA,

## **PROFESSIONAL BACKGROUND**

### **ACADEMIC APPOINTMENTS**

- 2017-** Graduate Faculty Status in the Department of Preventive Medicine and Public Health, University of Kansas Medical Center, Kansas City, KS
- 2011-present** Director, Division of Clinical Pharmacology, University of Kansas Medical Center, Kansas City, KS
- 2010-present** Professor, tenured, Department of Internal Medicine, University of Kansas Medical Center, Kansas City, KS
- 2004-2010** Associate Professor, Department of Internal Medicine, University of Kansas Medical Center, Kansas City, KS
- 2003-2011** Interim Director, Division of Clinical Pharmacology, University of Kansas Medical Center, Kansas City, KS
- 2002-present** Clinical Research Advisory committee, University of Kansas Medical Center, Kansas City, KS
- 2001-** Graduate Faculty, Department of Preventive Medicine, University of Kansas School of Pharmacy, Kansas City, KS
- 2000-present** Adjunct position in the Department of Pharmacy Practice, University of Kansas Medical Center, Kansas City, KS
- 1999-present** Medical Director, Atherosclerosis and LDL-Apheresis Clinic, University of Kansas Medical Center, Kansas City, KS
- 1998-** Center on Aging, University of Kansas Medical Center, Kansas City, KS
- 1998-2004** Assistant Professor, Department of Internal Medicine, University of Kansas Medical Center, Kansas City, KS

<b>1996-2000</b>	Medical Director, Utilization Review Board, University of Kansas Medical Center, Kansas City, KS
<b>1996-2000</b>	Medical Director, Medical Floors, University of Kansas Medical Center, Kansas City, KS
<b>1994-1998</b>	Clinical Assistant Professor, Department of Internal Medicine, University of Kansas Medical Center, Kansas City, KS
<b>1991-1994</b>	Internal Medicine Residency, University of Kansas Medical Center, Kansas City, KS

### **PROFESSIONAL & SOCIETY MEMBERSHIPS**

<b>2019</b>	Fellow of the European Society of Cardiology
<b>2015</b>	National Board of Physicians and Surgeons
<b>2012</b>	American College of Cardiology
<b>2012</b>	American Heart Association
<b>2012</b>	American Medical Association (includes JAMA)
<b>2012</b>	International Society for Apheresis
<b>2012</b>	National Lipid Association
<b>2012</b>	Society of Rheology
<b>2012</b>	Fellow of the National Lipid Association
<b>2012-2015</b>	President – International Society for Apheresis
<b>2010</b>	Board of Directors Member – Midwest Lipid Association
<b>2009</b>	Board of Directors Member – International Society for Atherosclerosis
<b>2006</b>	Fellow American College of Cardiology
<b>2005-2011</b>	National Lipid Association
<b>2005-2010</b>	Midwest Lipid Association
<b>2005</b>	European Atherosclerosis Society
<b>2005</b>	Society of Atherosclerosis Imaging
<b>2005</b>	International Society for Cellular Therapy
<b>2004</b>	American Society of Clinical Pharmacological Therapeutics
<b>2004</b>	American Heart Association/American Stroke Association
<b>2003-2007</b>	Kansas Chapter Advisory Council-American College of Physicians
<b>2003</b>	Fellow American College of Physicians
<b>2003-2004</b>	National Scientific Internal Medicine Advisory Board
<b>2001</b>	National Lipid Education Council
<b>2001</b>	American Diabetes Association Professional Section
<b>2001</b>	KUMC School of Medicine Murphy Academic Society
<b>2001-2005</b>	Missouri State Medical Association
<b>1996-1997</b>	Kansas City Internal Medicine Society - President

<b>1995</b>	International Atherosclerosis Society
<b>1995</b>	Arteriosclerosis, Thrombosis & Vascular Biology Council of the American Heart Association
<b>1994</b>	American College of Physicians

### **ACADEMIC TEACHING ACTIVITIES**

<b>2008</b>	Member “Who’s Who in Diabetes Treatment, Education and Research
<b>2005-present</b>	Resident core curriculum “Hyperlipidemia”
<b>2005-present</b>	Faculty Student Interaction “Dyslipidemia”
<b>2003-2004</b>	Health Promotion Disease Prevention “Secondary Prevention of CVD: HTN/Cholesterol”
<b>2003-2004</b>	Ambulatory “Atherosclerosis-Primary & Secondary Prevention”
<b>2003-present</b>	Instructor “Early Diagnosis and Treatment of Asymptomatic Vascular Disease”, University of Kansas Medical Center
<b>2002-2004</b>	Clinical Preceptor & Course Teacher-for second year medical students in “Clinical Skills”
<b>2002</b>	Program Director “Differential Stratification for risk of Cardiovascular Disease Symposium III”, University of Kansas, Continuing Education
<b>2000-2015</b>	Co-Director KU Medical Center’s Annual Drive-Through Flu Shot Clinic
<b>2000</b>	Program Director “Differential Stratification for risk of Cardiovascular Disease Symposium II”, University of Kansas, Continuing Education
<b>2000-present</b>	Career Advising Program (CAP) Faculty Advisor
<b>2000</b>	Mini Medical School, “Cholesterol/Atherosclerosis and Their Relationship to Cardiovascular Disease,”
<b>2000, 2002</b>	Program Questionnaire: Update on Risk Factors and Their Association with Cardiovascular Disease and Differential Stratification for the Risk of Cardiovascular Disease II, University of Kansas, Continuing Medical Education
<b>2000-2002</b>	Coordinator- Medicine Grand Rounds Annually
<b>1996-2000</b>	Morning Report, University of Kansas Medical Center
<b>1998-present</b>	Pharmacy Residents training in Atherosclerosis Prevention Clinic
<b>1998</b>	Program Director “Differential Stratification for the Risk of Cardiovascular Disease I and Update on Risk Factors and Their Association with Cardiovascular Disease, University of Kansas, Continuing Medical Education
<b>1998-present</b>	Medical students, residents training in the Atherosclerosis Prevention Clinic
<b>1997-</b>	Quarterly Atherosclerosis Lecture for Students/Residents
<b>1995-</b>	Medical Ethics Course, University of Kansas Medical School

<b>1994-present</b>	Physical Diagnosis for Medical Students
<b>1994-2005</b>	Attending Physician for Medical Residents and Students
<b>1994-2003</b>	Staff physician for medical residents and students rotation through General Medicine Clinics
<b>1989-1991</b>	Instructor for Medical Board course preparation, University of Missouri, Kansas City, MO.

### **ACADEMIC AWARDS**

<b>2025</b>	Attending Physician of the Year: Quality Improvement and Research
<b>2016</b>	MWLA President's Service Award
<b>2001</b>	Student Voice Excellence in Teaching Award
<b>1998</b>	Merck Young Investigator's Award
<b>1998</b>	The John A. Hartford Foundation Award as a research trainee
<b>1997</b>	The Max S. Allen, MD, Clinical Fellowship in Internal Medicine
<b>1997</b>	Student Voice Excellence in Teaching Award
<b>1992</b>	Mark Beck Award, Resident of the Year, University of Kansas Medical Center

### **HOSPITAL & RESEARCH COMMITTEE APPOINTMENTS**

<b>2013</b>	Data Monitoring Committee (I5S-EFJE Study)
<b>2008</b>	Internal Medicine Pharmaceutical Policy Committee
<b>2007</b>	CTSA Private Sector Advisory Committee
<b>2007</b>	E-research Sub-Committee
<b>2006</b>	Executive Vice-Chairman's Kansas City Metro Hospital Affiliation Committee
<b>2006</b>	Executive Vice-Chairman's By-laws Committee
<b>2006</b>	Data Safety and Monitoring Executive Committee
<b>2004</b>	General Clinic Research Center
<b>2002</b>	Clinical Research Advisory Committee
<b>1999-2003</b>	Board Member, K.U. Hospital Quality Council
<b>1996-1998</b>	Medical Director, Medical Floors
<b>1996-2000</b>	President, Utilization Review Committee
<b>1996-2000</b>	Founder & Director, Silver City Health Clinic
<b>1996-1998</b>	MPH Graduate Thesis Committee

### **EDITORIAL ACTIVITIES**

### **MANUSCRIPT REVIEWER**

*Clinical Cardiology*

*Atherosclerosis*

*Arteriosclerosis, Thrombosis, and Vascular Biology*

*Cardiovascular Drugs and Therapy*  
*Journal of Clinical Apheresis*  
*Future Lipidology*  
*Circulation*  
*Clinica Chimica Acta*  
*Journal of Stroke & Cerebrovascular Diseases*  
*American Journal of Cardiology Therapeutic Apheresis and Dialysis Metabolism*  
*Clinical and Experimental Nephrology Dialysis Transplantation Circulation*  
*Circulation Research*  
*Lancet*  
*Journal of Clinical Lipidology*  
*Drug Design, Development and Therapy*  
*Expert Opinion on Biological Therapy*  
*Journal of American College of Cardiology*  
*Journal of Thrombosis and Thrombolysis*  
*Therapeutic Apheresis and Dialysis*

### **ASSOCIATE EDITOR**

*Journal of Clinical Apheresis*  
*Future Lipidology*

### **BIBLIOGRAPHY**

#### **PUBLICATIONS: Manuscripts**

1. Dujovne CA, **Moriarty PM**. Clinical pharmacologic concepts for the rational selection and use of drugs for the management of dyslipidemia. *Clinical therapeutics*. 1996 May 1;18(3):392-410.
2. **Moriarty PM**. Relative risk reduction versus number needed to treat as measures of lipid-lowering trial results. *American Journal of Cardiology*. 1998 Aug 15;82(4):505-7.
3. **Moriarty PM**, Gibson CA. Low-density lipoprotein apheresis in the treatment of atherosclerosis and other potential uses. *Current atherosclerosis reports*. 2001 Mar 1;3(2):156-62.
4. **Moriarty PM**. Using both “relative risk reduction” and “number needed to treat” in evaluating primary and secondary clinical trials of lipid reduction. *American Journal of Cardiology*. 2001 May 15;87(10):1206-8.
5. **Moriarty PM**, Gibson CA, Shih J, Matias MS. C-reactive protein and other markers of inflammation among patients undergoing HELP LDL apheresis. *Atherosclerosis*. 2001 Oct 1;158(2):495-8.

6. **Moriarty PM**, Gibson, CA. A Familial Hypercholesterolemic Patient Treated with Heparin-Induced Extracorporeal LDL Precipitation (HELP). February 8, 2002. Lipid Management Newsletter for the NLEC, 2002.
7. **Moriarty, PM**. Cardiovascular Controversies in Postmenopausal Women Contemporary OB/GYN, 2002.
8. **Moriarty PM**, Gibson CA, Mayo MS, Vacek JL, Tadros P, Owens, SD. A Study to Demonstrate the Utility of HELP LDL Apheresis Treatment for Patients with Non-ST Elevation Acute Coronary Syndrome. *Atherosclerosis*, Vol 3, No 2. June (2002) 166-167.
9. Backes JM, **Moriarty PM**, Gibson CA. The effect of micronized fenofibrate on lipid profiles of patients converted from gemfibrozil. *Hospital Pharmacy*. 2002 Sep;37(9):953-6.
10. **Moriarty PM**, Backes JM. Effect of Atorvastatin and Bezafibrate on plasma levels of C-reactive protein in combined (mixed) hyperlipidemia. *Atherosclerosis*. 2003;166(1).
11. Hiles T, **Moriarty PM**. Pulse Pressure and Risk of Cardiovascular Disease, *Journal of American Medical Association*, 289, No.2 January (2003) 174-175.
12. **Moriarty PM**, Gibson CA. LDL apheresis and its effect on viscosity. *Cardiovascular reviews & reports*. 2003;24(6):321-5.
13. Backes JM, Howard PA, **Moriarty PM**. Role of C-reactive protein in cardiovascular disease. *Annals of Pharmacotherapy*. 2004 Jan;38(1):110-8.
14. **Moriarty PM**, Gibson CA, Kensey KR, Hogenauer W. Effect of low-density lipoprotein cholesterol apheresis on blood viscosity. *The American journal of cardiology*. 2004 Apr 15;93(8):1044-6.
15. **Moriarty PM**, Gibson CA, Kensey KR, Hogenauer W. Effect of low-density lipoprotein cholesterol apheresis on blood viscosity. *The American journal of cardiology*. 2004 Apr 15;93(8):1044-6.
16. Backes J, **Moriarty PM**, Calish JS, Gibson C. Fenofibrate impacts a greater number of cardiovascular risk factors compared to atorvastatin in treating mixed dyslipidemia among patients with metabolic syndrome or type 2 diabetes mellitus. *Pharmacotherapy*, 2005;25:454-55.
17. **Moriarty PM**, Whittaker TJ. Treatment of acute occlusion of the retinal artery by LDL-apheresis. *Journal of Clinical Apheresis: The Official Journal of the American Society for Apheresis*. 2005 Jul;20(2):88-92.

18. **Moriarty PM**, Gibson CA. Association between hematological parameters and high-density lipoprotein cholesterol. *Current opinion in cardiology*. 2005 Jul 1;20(4):318-23.
19. **Moriarty PM**. LDL-apheresis therapy: current therapeutic practice and potential future use. *Future Lipidology*. 2006 Jun 1;1(3):299-308.
20. **Moriarty PM**. LDL-apheresis Therapy. *Curr Treat Options Cardiovasc Med*. 2006 Aug; 8(4): 282-8.
21. Backes JM, Gibson CA, Ruisinger JF, **Moriarty PM**. Fibrates: what have we learned in the past 40 years? *Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy*. 2007 Mar;27(3):412-24.
22. Backes JM, **Moriarty PM**, Ruisinger JF, Gibson CA. Effects of once weekly rosuvastatin among patients with a prior statin intolerance. *The American journal of cardiology*. 2007 Aug 1;100(3):554-5.
23. **Moriarty PM**, Whittaker TJ. Apheresis therapy for retinal vasculitis. *Archives of Ophthalmology*. 2007 Oct 1;125(10):1443-.
24. Opole IO, Belmont JM, Kumar A, **Moriarty PM**. Effect of low-density lipoprotein apheresis on inflammatory and noninflammatory high-density lipoprotein cholesterol. *The American journal of cardiology*. 2007 Nov 1;100(9):1416-8.
25. Backes JM, Venero CV, Gibson CA, Ruisinger JF, Howard PA, Thompson PD, **Moriarty PM**. Effectiveness and tolerability of every-other-day rosuvastatin dosing in patients with prior statin intolerance. *Annals of Pharmacotherapy*. 2008 Mar;42(3):341-6.
26. Ruisinger JF, Backes JM, Gibson CA, **Moriarty PM**. Once-a-week rosuvastatin (2.5 to 20 mg) in patients with a previous statin intolerance. *The American journal of cardiology*. 2009 Feb 1;103(3):393-4.
27. Backes JM, Ruisinger JL, **Moriarty PM**. Sitagliptin-Lovastatin and Possible Rhabdomyolysis: Correlation and Mechanism Unknown. *Pharmacotherapy* 2009 29(5):174e-175e.
28. **Moriarty PM**. Association of ApoE and HDL. C with cardiovascular and cerebrovascular disease: potential benefits of LDL-apheresis therapy. *Clinical Lipidology*. 2009 Jun 1;4(3):311-29.

29. Backes JM, Howard PA, Ruisinger JF, **Moriarty PM**. Does simvastatin cause more myotoxicity compared with other statins? *Annals of Pharmacotherapy*. 2009 Dec;43(12):2012-20.
30. Ruisinger JF, Koerner JM, Backes JM, **Moriarty PM**. Supratherapeutic Response to Ezetimibe in a Statin Intolerant Patient. *Hospital Pharmacy*. 2010 Jan;45(1):45-8.
31. **Moriarty PM**, Sosland R, Gibson C, Belmont J. Comparison of different low density lipoprotein apheresis machines on brain natriuretic peptide levels in patients with familial hypercholesterolemia. *Therapeutic Apheresis and Dialysis*. 2010 Feb;14(1):74-8.
32. Sosland RP, Gollub SB, Wilson DB, **Moriarty PM**. The first case report of the treatment of transplant coronary artery disease with dextran sulfate adsorption lipid apheresis. *Therapeutic Apheresis and Dialysis*. 2010 Apr;14(2):218-21.
33. Bulchandani D, **Moriarty PM**. Acute Reduction of Lipoprotein (a) After Low-Density Lipoprotein Apheresis May Improve Symptoms of Angina\*. *Journal of Clinical Lipidology*. 2010 May 1;4(3):217-8.
34. **Moriarty PM**, Luyendyk JP, Gibson CA, Backes JM. Effect of low-density lipoprotein apheresis on plasma levels of apolipoprotein e4. *The American journal of cardiology*. 2010 Jun 1;105(11):1585-7.
35. Ito MK, McGowan MP, **Moriarty PM**. Management of familial hypercholesterolemia in adult patients: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. *Journal of clinical lipidology*. 2011 Jun 1;5(3):S38-45.
36. Backes JM, Barnes BJ, Ruisinger JF, **Moriarty PM**. A comparison of 25-hydroxyvitamin D serum levels among those with or without statin-associated myalgias. *Atherosclerosis*. 2011 Sep 1;218(1):247-9.
37. Backes JM, Padley RJ, **Moriarty PM**. Important considerations for treatment with dietary supplement versus prescription niacin products. *Postgraduate medicine*. 2011 Mar 1;123(2):70-83.
38. Goldberg AC, Hopkins PN, Toth PP, Ballantyne CM, Rader DJ, Robinson JG, Daniels SR, Gidding SS, De Ferranti SD, Ito MK, McGowan MP, **Moriarty PM**, et al. Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. *Journal of clinical lipidology*. 2011 May 1;5(3):133-40.

39. Backes JM, Gibson CA, Ruisinger JF, **Moriarty PM**. Modified policosanol does not reduce plasma lipoproteins in hyperlipidemic patients when used alone or in combination with statin therapy. *Lipids*. 2011 Oct 1;46(10):923-9.
40. Brown WV, Brook R, Hemphill LC, **Moriarty PM**. The use of lipopheresis in the practice of clinical lipidology. *Journal of clinical lipidology*. 2012 Mar 1;6(2):98-104.
41. Duell PB, Santos RD, East C, Guyton JR, **Moriarty PM**, Donovan JM, Mittleman RS. Long-term safety and efficacy of mipomersen in patients with familial hypercholesterolemia uncontrolled by maximally tolerated lipid lowering therapy. *Journal of Clinical Lipidology*. 2012 May 1;6(3):291.
42. Owens AP, Passam FH, Antoniak S, Marshall SM, McDaniel AL, Rudel L, Williams JC, Hubbard BK, Dutton JA, Wang J, Tobias PS, Curtiss LK, Daugherty A, Kirchhofer D, Luyendyk JP, **Moriarty PM**, Nagarajan S, Furie BC, Furie B, Johns DG, Temel RE, Machman N. Monocyte tissue factor-dependent activation of coagulation in hypercholesterolemic mice and monkeys is inhibited by simvastatin. *The Journal of clinical investigation*. 2012 Feb 1;122(2):558-68.
43. Backes JM, Gibson CA, Ruisinger JF, **Moriarty PM**. The high-dose rosuvastatin once weekly study (the HD-ROWS). *Journal of clinical lipidology*. 2012 Jul 1;6(4):362-7.
44. Backes JM, Dayspring T, Mieras T, **Moriarty PM**. Pseudo hypertriglyceridemia: two cases of probable glycerol kinase deficiency. *Journal of clinical lipidology*. 2012 Sep 1;6(5):469-73.
45. **Moriarty PM**, Backes J, Dutton JA, He J, Ruisinger JF, Schmelzle K. Apple pectin for the reduction of niacin-induced flushing. *Journal of clinical lipidology*. 2013 Mar 1;7(2):140-6.
46. Backes JM, Dayspring T, **Moriarty PM**. Pseudo hypertriglyceridemia-verifying the hypertriglyceridemic patient. *Journal of clinical lipidology*. 2013 Mar 1;7(2):182-3.
47. **Moriarty PM**. A Hungarian rhapsody in lipids. *Clinical Lipidology*. 2013 Apr 1;8(2):183-5.
48. Grand'Maison F, Bhan V, Freedman MS, Myles ML, Patry DG, Selchen DH, **Moriarty PM**, Traboulsee AL. Utility of the Canadian treatment optimization recommendations (TOR) in MS care. *Canadian journal of neurological sciences*. 2013 Jul;40(4):527-35.

49. **Moriarty PM**, Lecorps G, Hanotin C, Pordy R, Roth EM. Homogeneity of treatment effect of REGN727/SAR236553, a fully human monoclonal antibody against PCSK9, in lowering LDL-C: data from three phase 2 studies. *European heart journal*. 2013 Aug 1;34(suppl\_1):142.
50. Backes JM, Ruisinger JF, Harris KA, Gibson CA, Harris WS, **Moriarty PM**. Evaluating the Effects of Prescription Fish Oil, Supplemental Fish Oil and a Krill Oil Blend on Serum Lipids/Lipoproteins and the Omega-3 Index: A Pilot Study. *Journal of Glycomics & Lipidomics*. 2014 Jan 1;4(4):1.
51. Roth EM, **Moriarty PM**, Li S, Duan Z, Guo S, Liu P, Zhao J, Zhang Y. Red yeast rice extract shows equivalency to statins.
52. McGowan MP, **Moriarty PM**, Backes JM. The effects of mipomersen, a second-generation antisense oligonucleotide, on atherogenic (apoB-containing) lipoproteins in the treatment of homozygous familial hypercholesterolemia. *Clinical Lipidology*. 2014 Oct 1;9(5):487-503.
53. **Moriarty PM**, Jacobson TA, Bruckert E, Thompson PD, Guyton JR, Baccaradinet MT, Gipe D. Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: design and rationale of ODYSSEY ALTERNATIVE, a randomized phase 3 trial. *Journal of clinical lipidology*. 2014 Nov 1;8(6):554-61.
54. **Moriarty PM**, Roth EM, Karns A, Ye P, Zhao SP, Liao Y, Capuzzi DM, Bays HE, Zhang F, Liu S, Reichman AJ. Effects of Xuezhikang in patients with dyslipidemia: a multicenter, randomized, placebo-controlled study. *Journal of clinical lipidology*. 2014 Nov 1;8(6):568-75.
55. Backes JM, Dayspring TD, Hoefner DM, Contois JH, McConnell JP, **Moriarty PM**. Identifying pseudo hypertriglyceridemia in clinical practice. *Clinical Lipidology*. 2014 Dec 1;9(6):625-41.
56. Ruisinger JF, Gibson CA, Backes JM, Smith BK, Sullivan DK, **Moriarty PM**, Kris-Etherton P. Statins and almonds to lower lipoproteins (the STALL Study). *Journal of clinical lipidology*. 2015 Jan 1;9(1):58-64.
57. Michalska-Kasiczak M, Sahebkar A, Mikhailidis DP, Rysz J, Muntner P, Toth PP, Jones SR, Rizzo M, Hovingh GK, Farnier M, **Moriarty PM**. Analysis of vitamin D levels in patients with and without statin-associated myalgia—a systematic review and meta-analysis of 7 studies with 2420 patients. *International journal of cardiology*. 2015 Jan 15;178:111-6.
58. Santos RD, Duell PB, East C, Guyton JR, **Moriarty PM**, Chin W, Mittleman RS. Long-term efficacy and safety of mipomersen in patients with familial

- hypercholesterolemia: 2-year interim results of an open-label extension. *European heart journal*. 2015 Mar 1;36(9):566-75.
59. O'Brien EC, DeGoma E, **Moriarty PM**, Linton MF, Shapiro M, Duell B, Ballantyne C, Neal W, Ahmad Z, Duffy D, Hudgins L. Initial results from the CASCADE-FH registry: cascade screening for awareness and detection of familial hypercholesterolemia. *Journal of the American College of Cardiology*. 2015 Mar 17;65(10 Supplement):A1372.
  60. Stefanutti C, D'Alessandri G, Petta A, Harada-Shiba M, Julius U, Soran H, **Moriarty PM**, Romeo S, Drogari E, Jaeger BR. First on-line survey of an international multidisciplinary working group (Mighty Medic) on current practice in diagnosis, therapy and follow-up of dyslipidemias. *Atherosclerosis Supplements*. 2015 May 1;18:241-50.
  61. Anabtawi A, Patel P, Deuschle L, **Moriarty PM**. Long-Term Follow Up of Bi-Weekly Lipoprotein Apheresis in A patient with Elevated Lipoprotein-(a) Shows Regression in Carotid Intima-Media Thickness. *Journal of Clinical Lipidology*. 2015 May 1;9(3):453.
  62. Winters JL, Cooper LT, Ratcliffe NR, Wu Y, **Moriarty PM**. National heart, lung, and blood institute state of the science symposium in therapeutic apheresis—Therapeutic apheresis in cardiovascular disease. *Journal of clinical apheresis*. 2015 Jun;30(3):183-7.
  63. Banach M, Rizzo M, Toth PP, Farnier M, Davidson MH, Al-Rasadi K, Aronow WS, Athyros V, Djuric DM, Ezhov MV, Greenfield RS, Hovingh GK, Kostner K, Serban C, Lighezan D, Flas Z, **Moriarty PM**, Muntner P, Goudey A, Ceska R, Nicholls SJ, Broncel M, Nikolic D, Pella D, Puri R, Rysz J, Wong ND, Bajnok L, Jones SR, Ray KK, Mikhailidis DP. Statin intolerance—an attempt at a unified definition. Position paper from an International Lipid Expert Panel: This paper is also published in parallel in *Archives of Medical Science* [Banach M, Rizzo M, Toth PP, et al. Statin intolerance—an attempt at a unified definition. Position paper from an International Lipid Expert Panel. *Arch Med Sci* 2015; 11 (1): 1–23]. Expert opinion on drug safety. 2015 Jun 3;14(6):935-55.
  64. Backes JM, Ruisinger JF, Barnes BJ, **Moriarty PM**. Statin intolerance and vitamin D supplementation: Sunny, but a few clouds remain... *North Am J Med Sci* 2015;7:337-8
  65. Backes JM, Dayspring TD, Hoefner DM, **Moriarty PM**. Hypertriglyceridemia unresponsive to multiple treatments. *Case Reports*. 2015 Oct 14;2015:bcr2015210788.

66. **Moriarty PM**, Thompson PD, Cannon CP, Guyton JR, Bergeron J, Zieve FJ, Bruckert E, Jacobson TA, Kopecky SL, Baccara-Dinet MT, Du Y. Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: the ODYSSEY ALTERNATIVE randomized trial. *Journal of clinical lipidology*. 2015 Nov 1;9(6):758-69.
67. **Moriarty PM**. Lipoprotein apheresis: present and future uses. *Current opinion in lipidology*. 2015 Dec 1;26(6):544-52.
68. Brown WV, **Moriarty PM**, McKenney JM. JCL roundtable: PCSK9 inhibitors in clinical practice. *Journal of clinical lipidology*. 2016 Jan 1;10(1):5-14.
69. Brown WV, **Moriarty PM**, Remaley AT, Tsimikas S. JCL Roundtable: Should we treat elevations in Lp (a)? *Journal of clinical lipidology*. 2016 Mar 1;10(2):215-24.
70. **Moriarty PM**, Hemphill L. Lipoprotein Apheresis. *Endocrinol Metab Clin North Am*. 2016 Mar;45(1):39-54. doi: 10.1016/j.ecl.2015.09.003. PMID: 26892996.
71. **Moriarty PM**, Thiessen ES, Witztum JL, Viney NJ, Tsimikas S. Rationale and design of a clinical trial to assess Lp(a) lowering with Ionis-apo(a)-LRX in patients undergoing apheresis for elevated Lp(a) and recurrent cardiovascular events. 2016;252:e123.
72. Degoma EM, Ahmad ZS, O'Brien EC, Kindt I, Shrader P, Newman CB, Pokharel Y, Baum SJ, Hemphill LC, Hudgins LC, Ahmed CD, Gidding SS, Duffy D, Neal W, Wilemon K, Roe MT, Rader DJ, Ballantyne CM, Linton MF, Duell PB, Shapiro MD, **Moriarty PM**, Knowles JW. Treatment gaps in adults with heterozygous familial hypercholesterolemia in the United States: data from the CASCADE-FH registry. *Circulation: Cardiovascular Genetics*. 2016 Jun;9(3):240-9.
73. Ahmad ZS, Andersen RL, Andersen LH, O'Brien EC, Kindt I, Shrader P, Vasandani C, Newman CB, deGoma EM, Baum SJ, Hemphill LC, Hudgins LC, Ahmed CD, Kullo IJ, Gidding SS, Duffy D, Neal W, Wilemon K, Roe MT, Rader DJ, Ballantyne CM, Linton MF, Duell PB, Shapiro MD, **Moriarty PM**, Knowles JW. US physician practices for diagnosing familial hypercholesterolemia: data from the CASCADE-FH registry. *Journal of clinical lipidology*. 2016 Sep 1;10(5):1223-9.
74. Santos RD, Gidding SS, Hegele RA, Cuchel MA, Barter PJ, Watts GF, Baum SJ, Catapano AL, Chapman MJ, Defesche JC, Folco E, Freiburger T, Genest J, Hovingh GK, Harada-Shiba M, Humphries SE, Jackson AS, Mata P, **Moriarty PM**, Raal FJ, Al-Rasadi K, Ray KK, Reiner Z, Sijbrands EJG, Yamashita S.

- Defining severe familial hypercholesterolemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel. *The lancet Diabetes & endocrinology*. 2016 Oct 1;4(10):850-61.
75. **Moriarty PM**, Badawi AH, Lepping RJ, et al. External Counterpulsation Therapy for Patients with Mild Cognitive Impairment. Austin Publishing Group. Austin J Clin Med - Volume 3 Issue 2 – 2016. ISSN : 2381-9146
  76. **Moriarty PM**, Parhofer KG, Babirak SP, Cornier MA, Duell PB, Hohenstein B, Leebmann J, Ramlow W, Schettler V, Simha V, Steinhagen-Thiessen E. Alirocumab in patients with heterozygous familial hypercholesterolemia undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trial. *European heart journal*. 2016 Dec 21;37(48):3588-95.
  77. Roth EM, **Moriarty PM**, Bergeron J, Langslet G, Manvelian G, Zhao J, Baccara-Dinet MT, Rader DJ. ODYSSEY CHOICE I investigators. A phase III randomized trial evaluating alirocumab 300 mg every 4 weeks as monotherapy or add-on to statin: ODYSSEY CHOICE I. *Atherosclerosis*. 2016;254:254-62.
  78. Harris ES, Meiselman HJ, **Moriarty PM**, Weiss J. Successful long-term (22 year) treatment of limited scleroderma using therapeutic plasma exchange: Is blood rheology the key? *Clinical hemorheology and microcirculation*. 2017 Jan 1;65(2):131-6.
  79. Backes JM, Ruisinger JF, Gibson CA, **Moriarty PM**. Statin-associated muscle symptoms—managing the highly intolerant. *Journal of clinical lipidology*. 2017 Jan 1;11(1):24-33.
  80. Heintz RE, Tennant HM, Ricketts JC, Rice CR, Robinson CB, Sandesara PB, **Moriarty PM**, Sperling L. Lipoprotein-X disease in the setting of severe cholestatic hepatobiliary autoimmune disease. *Journal of clinical lipidology*. 2017 Jan 1;11(1):282-6.
  81. **Moriarty PM**, Varvel SA, Gordts PL, McConnell JP, Tsimikas S. Lipoprotein (a) mass levels increase significantly according to APOE genotype: an analysis of 431 239 patients. *Arteriosclerosis, thrombosis, and vascular biology*. 2017 Mar;37(3):580-8.
  82. Stefanutti C, Julius U, Watts GF, Harada-Shiba M, Cossu M, Schettler VJ, De Silvestro G, Soran H, Van Lennep JR, Pisciotto L, Klör HU, Widhalm K, **Moriarty PM**, and the MIGHTY MEDIC Multinational Society. Toward an international consensus—Integrating lipoprotein apheresis and new lipid-lowering drugs. *Journal of clinical lipidology*. 2017 Jul 1;11(4):858-71.

83. Awad K, Mikhailidis DP, Toth PP, Jones SR, **Moriarty PM**, Lip GY, Muntner P, Catapano AL, Pencina MJ, Rosenson RS, Rysz J. Efficacy and safety of alternate day versus daily dosing of statins: a systematic review and meta-analysis. *Cardiovascular drugs and therapy*. 2017 Aug 1;31(4):419-31.
84. Rosenson RS, Baker S, Banach M, Borow KM, Braun LT, Bruckert E, Brunham LR, Catapano AL, Elam MB, Mancini GJ, **Moriarty PM**. Optimizing cholesterol treatment in patients with muscle complaints. *Journal of the American College of Cardiology*. 2017 Aug 28;70(10):1290-301.
85. Amrock SM, Duell PB, Knickelbine T, Martin SS, O'Brien EC, Watson KE, Mitri J, Kindt I, Shrader P, Baum SJ, Hemphill LC, Ahmed CD, Andersen RL, Kullo IJ, McCann D, Larry JA, Murray MF, Fishberg R, Guyton JR, Wilemon K, Roe MT, Rader DJ, Ballantyne CM, Underberg JA, Thompson P, Duffy D, Linton MF, Shapiro MD, **Moriarty PM**, Knowles JW, Ahmad ZS. Health disparities among adult patients with a phenotypic diagnosis of familial hypercholesterolemia in the CASCADE-FH™ patient registry. *Atherosclerosis*. 2017 Dec;267:19-26. doi: 10.1016/j.atherosclerosis.2017.10.006. Epub 2017 Oct 6. PMID: 29080546.
86. **Moriarty PM**, Tennant H, Sehar N, Denney L, Luna P, Perez-Marques F, Panchal A, Abraham M, Leever J. Case report of male child with elevated lipoprotein (a) leading to acute ischemic stroke. *Journal of clinical apheresis*. 2017 Dec;32(6):574-8.
87. Anabtawi A, **Moriarty PM**, Miles JM. Pharmacologic treatment of dyslipidemia in diabetes: A case for therapies in addition to statins. *Curr Cardiol Rep*. 2017;19(7):62.
88. Hovingh GK, Goldberg AC, **Moriarty PM**. Managing the challenging homozygous familial hypercholesterolemia patient: Academic insights and practical approaches for a severe dyslipidemia, a National Lipid Association Masters Summit.
89. Tsimikas S, Fazio S, Ferdinand KC, Ginsberg HN, Koschinsky ML, Marcovina SM, **Moriarty PM**, Rader DJ, Remaley AT, Reyes-Soffer G, Santos RD. NHLBI working group recommendations to reduce lipoprotein (a)-mediated risk of cardiovascular disease and aortic stenosis. *Journal of the American College of Cardiology*. 2018 Jan 8;71(2):177-92.
90. Ruisinger JF, **Moriarty PM**, Backes JM. Coenzyme Q10 for statin-associated myalgia. *The Bulletin of the American Society of Hospital Pharmacists*. 2018 Jan 15;75(2):14-5.

91. Funk RS, Singh RK, Winefield RD, Kandel SE, Ruisinger JF, **Moriarty PM**, Backes JM. Variability in potency among commercial preparations of berberine. *Journal of dietary supplements*. 2018 May 4;15(3):343-51.
92. Banach M, Patti AM, Giglio RV, Cicero AF, Atanasov AG, Bajraktari G, Bruckert E, Descamps O, Djuric DM, Ezhov M, Fras Z, **Moriarty PM**, et al. The role of nutraceuticals in statin intolerant patients. *Journal of the American College of Cardiology*. 2018 Jun 25;72(1):96-118.
93. **Moriarty PM**, Boffa MB, Koschinsky M. Clinical Feature: Lipoprotein(a)- Fast Facts and Clinical Perspectives. *MWLA Lipid Spin*. September 2018. 16(3): 7-10.
94. Boffa MB, Stranges S, Klar N, **Moriarty PM**, Watts GF, Koschinsky ML. Lipoprotein (a) and secondary prevention of atherothrombotic events: A critical appraisal. *Journal of clinical lipidology*. 2018 Nov 1;12(6):1358-66.
95. Marcovina SM, **Moriarty PM**, Koschinsky ML, Guyton JR. JCL roundtable—Lipoprotein (a): the emerging risk factor. *Journal of clinical lipidology*. 2018 Nov 1;12(6):1335-45.
96. **Moriarty PM**, Thompson PD, Cannon CP, Guyton JR, Bergeron J, Zieve FJ, Bruckert E, Jacobson TA, Baccara-Dinet MT, Zhao J, Donahue S. Efficacy and Safety of Alirocumab in Statin-Intolerant Patients Over 3 Years: Open-Label Extension of the ODYSSEY ALTERNATIVE Trial. *Circulation*. 2018 Nov 6;138(Suppl\_1):A12267-.
97. Reeskamp LF, Kastelein JJ, **Moriarty PM**, Duell PB, Catapano AL, Santos RD, Ballantyne CM. Safety and efficacy of mipomersen in patients with heterozygous familial hypercholesterolemia. *Atherosclerosis*. 2019 Jan 1;280:109-17.
98. Backes JM, Melton BL, Ruisinger JF, Burkhardt CD, **Moriarty PM**. Comparing patients' prescribed, self-reported, and actual intake of supplemental Eicosapentaenoic acid+ docosahexaenoic acid. *Journal of clinical lipidology*. 2019 Jan 1;13(1):170-5.
99. Backes JM, Dayspring T, **Moriarty PM**. Pseudo hypertriglyceridemia—Raising clinical awareness. *Journal of Clinical Lipidology*. 2019 Sep 1;13(5):855-6.
100. Duell PB, Gidding SS, Andersen RL, Knickelbine T, Anderson L, Gianos E, Shrader P, Kindt I, O'Brien EC, McCann D, Hemphill LC, Ahmed CD, Martin SS, Larry JA, Ahmad ZS, Kullo IJ, Underberg JA, Guyton J, Thompson P, Wilemon K, Roe MT, Rader DJ, Cuchel M, Linton MF, Shapiro MD, **Moriarty PM**, Knowles JW. Longitudinal low density lipoprotein cholesterol goal achievement and cardiovascular outcomes among adult patients with familial

- hypercholesterolemia: The CASCADE FH registry. *Atherosclerosis*. 2019 Oct 1;289:85-93.
101. Müller-Wieland D, Rader DJ, **Moriarty PM**, Bergeron J, Langslet G, Ray KK, Manvelian G, Thompson D, Bujas-Bobanovic M, Roth EM. Efficacy and Safety of Alirocumab 300 mg Every 4 Weeks in Individuals With Type 2 Diabetes on Maximally Tolerated Statin. *The Journal of Clinical Endocrinology & Metabolism*. 2019 Nov;104(11):5253-62.
  102. Baum SJ, Sampietro T, Datta D, **Moriarty PM**, Knusel B, Schneider J, Somaratne R, Kurtz C, Hohenstein B. Effect of Evolocumab on lipoprotein apheresis requirement and lipid levels: Results of the randomized, controlled, open-label DE LAVAL study. *Journal of clinical lipidology*. 2019 Nov 1;13(6):901-9.
  103. **Moriarty PM**, Gray JV, Gorby LK. Lipoprotein apheresis for lipoprotein (a) and cardiovascular disease. *Journal of clinical lipidology*. 2019 Nov 1;13(6):894-900.
  104. Roe MT, Li QH, Bhatt DL, Bittner VA, Diaz R, Goodman SG, Harrington RA, Jukema JW, Lopez-Jaramillo P, Lopes RD, Louie MJ, **Moriarty PM**, et al. Risk categorization using new American College of Cardiology/American Heart Association guidelines for cholesterol management and its relation to alirocumab treatment following acute coronary syndromes. *Circulation*. 2019 Nov 5;140(19):1578-89.
  105. McGowan MP, Hosseini Dehkordi SH, **Moriarty PM**, Duell PB. Diagnosis and Treatment of Heterozygous Familial Hypercholesterolemia. *Journal of the American Heart Association*. 2019 Dec 17;8(24):e013225.
  106. O'Dea LS, MacDougall J, Alexander VJ, Digenio A, Hubbard B, Arca M, **Moriarty PM**, Kastelein JJ, Bruckert E, Soran H, Witztum JL. Differentiating familial chylomicronemia syndrome from multifactorial severe hypertriglyceridemia by clinical profiles. *Journal of the Endocrine Society*. 2019 Dec;3(12):2397-410.
  107. Tsimikas S, Karwatowska-Prokopczuk E, Gouni-Berthold I, Tardif JC, Baum SJ, Steinhagen-Thiessen E, Shapiro MD, Stroes ES, **Moriarty PM**, Nordestgaard BG, Xia S. Lipoprotein (a) Reduction in Persons with Cardiovascular Disease. *New England Journal of Medicine*. 2020 Jan 1.
  108. **Moriarty PM**, Thompson PD, Cannon CP, Guyton JR, Bergeron J, Zieve FJ, Bruckert E, Jacobson TA, Baccara-Dinet MT, Zhao J, Donahue S. Efficacy and safety of alirocumab in statin-intolerant patients over 3 years: open-label treatment period of the ODYSSEY ALTERNATIVE trial. *Journal of Clinical Lipidology*. 2020 Jan 13.

109. Bittner VA, Szarek M, Aylward PE, Bhatt DL, Diaz R, Edelberg JM, et al. Effect of Alirocumab on lipoprotein(a) and cardiovascular risk after acute coronary syndrome. *J Am Coll Cardiol*. 2020;75(2):133-44.
110. Nugent AK, Gray JV, Gorby LK, **Moriarty PM**. Lipoprotein Apheresis: First FDA Indicated Treatment for Elevated Lipoprotein (a). *J Clin Cardiol*. 2020;1(1):17.
111. **Moriarty PM**, Gorby LK, Stroes ES, Kastelein JP, Davidson M, Tsimikas S. Lipoprotein (a) and Its Potential Association with Thrombosis and Inflammation in COVID-19: A Testable Hypothesis. *Current Atherosclerosis Reports*. 2020 Sep;22(9):1-8.
112. Nicholls SJ, Lincoff AM, Bays HE, Cho L, Grobbee DE, Kastelein JJ, Libby P, **Moriarty PM**, Plutzky J, Ray KK, Thompson PD. Rationale and design of the CLEAR-outcomes trial: Evaluating the effect of Bempedoic acid on cardiovascular events in patients with statin intolerance. *American Heart Journal*. 2020 Oct 24.
113. Goldberg AC, Dunbar RL, Hemphill L, Babirak SP, Wilson G, Wooten M, Iydroose M, Dacus K, Minchew H, Dutton JA, **Moriarty PM**. A retrospective analysis of clinical use of alirocumab in lipoprotein apheresis patients. *Journal of clinical lipidology*. 2020 Nov 1;14(6):818-24.
114. Szarek M, Bittner VA, Aylward P, Baccara-Dinet M, Bhatt DL, Diaz R, **Moriarty PM**, et al. Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial. *Eur Heart J*. 2020 Nov 21;41(44):4245-55.
115. Willeit P, Yeang C, **Moriarty PM**, Tschiderer L, Varvel SA, McConnell JP, Tsimikas S. Low-Density Lipoprotein Cholesterol Corrected for Lipoprotein(a) Cholesterol, Risk Thresholds, and Cardiovascular Events. *Journal of the American Heart Association*. 2020 Nov 23;9:e016318
116. Tsimikas S, **Moriarty PM**, Stroes ES. Emerging RNA Therapeutics to Lower Blood Levels of Lp(a). *Journal of The American College of Cardiology*. 2021 Jan 11. 10.1016/j.jacc.2021.01.051.
117. Wilson DP, Koschinsky ML, **Moriarty PM**. Expert position statements: comparison of recommendations for the care of adults and youth with elevated lipoprotein (a). *Current opinion in endocrinology, diabetes, and obesity*. 2021 Jan 28.
118. Zhubi-Bakija F, Bajraktari G, Bytyçi I, Mikhailidis DP, Henein MY, Latkovskis G, et al. The impact of type of dietary protein, animal versus vegetable, in

modifying cardiometabolic risk factors: A position paper from the International Lipid Expert Panel (ILEP). *Clin Nutr.* 2021;40(1):255-76.

119. Alexander E, **Moriarty PM**, Wilk B, Eliaz I. Establishing low-density lipoprotein apheresis tolerability in patients with prior anaphylactoid reactions to lipoprotein apheresis using magnesium sulfate. *Journal of Clinical Apheresis.* 2021 Feb 18.
120. Nicholls S, Lincoff AM, Bays HE, Cho L, Grobbee DE, Kastelein JJ, Libby P, **Moriarty PM**, Plutzky J, Ray KK, Thompson PD. Rationale and design of the CLEAR-outcomes trial: evaluating the effect of bempedoic acid on cardiovascular events in patients with statin intolerance. *American heart journal.* 2021 May 1;235:104-12.
121. Tsimikas S, **Moriarty PM**, Stroes ES. Emerging RNA therapeutics to lower blood levels of Lp (a): JACC Focus Seminar 2/4. *Journal of the American College of Cardiology.* 2021 Mar 30;77(12):1576-89.
122. Gouni-Berthold I, Alexander VJ, Yang Q, Hurh E, Steinhagen-Thiessen E, **Moriarty PM**, Hughes SG, Gaudet D, Hegele RA, O'Dea LS, Stroes ES. Efficacy and safety of Volanesorsen in patients with multifactorial chylomicronemia (COMPASS): a multicenter, double-blind, randomized, placebo-controlled, phase 3 trial. *The lancet Diabetes & endocrinology.* 2021 May 1;9(5):264-75.
123. Ranka S, Lahan S, Dalia T, Tripathi A, Goyal A, Sreenivasan J, Taduru S, Muhammed M, **Moriarty PM**. Association Between Red Cell Distribution Width and Cardiovascular Outcomes—Systematic Review and Meta-Analysis. *Medical Research Archives.* 2021 Jul 9;9(7).
124. Bjelakovic B, Stefanutti C, Reiner Ž, Watts GF, **Moriarty PM**, Marais D, Widhalm K, Cohen H, Harada-Shiba M, Banach M. Risk assessment and clinical management of children and adolescents with Heterozygous Familial Hypercholesterolemia. a position paper of the associations of preventive pediatrics of Serbia, mighty medic and international lipid expert panel. *Journal of Clinical Medicine.* 2021 Oct 25;10(21):4930.
125. Nurmohamed NS, Collard D, Reeskamp LF, Kaiser Y, Kroon J, Tromp TR, Amsterdam UM. Covid-19 Biobank, van den Born BH, Coppens M, Vlaar APJ, Beudel M, van de Beek D, van Es N, **Moriarty PM**, Tsimikas S, Stroes ESG. Lipoprotein (a), venous thromboembolism and COVID-19: A pilot study. *Atherosclerosis.* 2021;341:43-9.
126. Mozaffarian D, Maki KC, Bays HE, Aguilera F, Gould G, Hegele RA, **Moriarty PM**, Robinson JG, Shi P, Tur JF, Lapointe JF. Effectiveness of a novel  $\omega$ -3 krill oil agent in patients with severe hypertriglyceridemia: A randomized clinical trial. *JAMA network open.* 2022 Jan 4;5(1):e2141898.

127. Koren MJ, **Moriarty PM**, Baum SJ, Neutel J, Hernandez-Illas M, Weintraub HS, et al. Preclinical development and phase 1 trial of a novel siRNA targeting lipoprotein(a). *Nat Med.* 2022;28(1):96-103.
128. Tardif J-C, Karwatowska-Prokopczuk E, Amour ES, Ballantyne CM, Shapiro MD, **Moriarty PM**, et al. Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridemia and at high cardiovascular risk. *Eur Heart J.* 2022;43(14):1401-12.
129. Safarova MS, Nugent AK, Gorby L, Dutton JA, Thompson WJ, **Moriarty PM**. Effect of Lipoprotein Apheresis on Progression of Carotid Intima-Media Thickness in Patients with Severe Hypercholesterolemia. *The American Journal of Cardiology.* 2022 Jun 17.
130. Karwatowska-Prokopczuk E, Tardif JC, Gaudet D, Ballantyne CM, Shapiro MD, **Moriarty PM**, Baum SJ, St Amour E, Alexander VJ, Xia S, Otvos JD. Effect of Olezarsen targeting APOC-III on lipoprotein size and particle number measured by NMR in patients with hypertriglyceridemia. *Journal of Clinical Lipidology.* 2022 Jun 23.
131. **Moriarty PM**, Steg PG, McGinniss J, Zeiher AM, White HD, Manvelian G, et al. Relation of red blood cell distribution width to risk of major adverse cardiovascular events, death, and effect of Alirocumab after acute coronary syndromes. *J Clin Lipidol.* 2022;16(5):747-56.
132. Nurmohamed NS, **Moriarty PM**, Stroes ESG. Considerations for routinely testing for high Lp(a). *Curr Opin Lipidol.* 2022;33(3):213-8.
133. Kronenberg F, **Moriarty PM**, Mora S, Stroes ESG, Ference BA, Arsenault BJ, Berglund L, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. *Eur Heart J.* 2022;43(39):3925-46.
134. Deshotels MR, Hadley TD, Roth M, Agha AM, Pulipati VP, **Moriarty PM**, Nugent AK, et al. Genetic testing for hypertriglyceridemia in academic lipid clinics: Implications for precision medicine. *Arterioscler Thromb Vasc Biol.* 2022;42(12):1461-7.
135. Nissen SE, Lincoff AM, Brennan D, Ray KK, Mason D, Kastelein JJP, **Moriarty PM**, et al. Bempedoic acid and Cardiovascular outcomes in statin-intolerant patients. *N Engl J Med.* 2023; 10.1056/NEJMoa2215024
136. **Moriarty PM**, Gorby L, Safarova M, Salat D, Burns J, Moreno T, et al. External Counterpulsation on performance in patients with mild cognitive impairment or

- mild Alzheimer’s Disease: A randomized sham-controlled study. *J Am Coll Cardiol.* 2023;81(8):1642.
137. Cuchel M, Lee PC, Hudgins LC, Duell PB, Ahmed Z, Baum SJ, **Moriarty PM**, et al. Contemporary homozygous familial hypercholesterolemia in the United States: Insights from the CASCADE FH Registry. *J Am Heart Assoc.* 2023;12(11):e027706.
138. Safarova MS, **Moriarty PM**. Lipoprotein Apheresis: Current recommendations for treating familial hypercholesterolemia and elevated Lp(a). *Curr Atheroscler Rep.* 2023;25(7):391-404.
139. Katsiki N, Mikhailidis DP, Bajraktari G, Miserez AR, Cicero AFG, Bruckert E, **Moriarty PM**, et al. Statin therapy in athletes and patients performing regular intense exercise – Position paper from the International Lipid Expert Panel (ILEP). *Pharmacol Res [Internet].* 2020;155(104719):104719.
140. Wiegman A, Greber-Platzer S, Ali S, Doortje Reijman M, Brinton EA, Charng, M-J, **Moriarty PM**, et al. Evinacumab for Pediatric Patient with Homozygous Familial Hypercholesterolemia. *Circulation.*
141. Gianos E, Duell PB, Toth PP, **Moriarty PM**, Thompson GR, Brinton EA, et al. Lipoprotein Apheresis: Utility, Outcomes, and Implementation in Clinical Practice: A Scientific Statement from the American Heart Association. *Arterioscler Thromb Vasc Biol [Internet].* 2024;44(12):e304-21.

## **RESEARCH ACTIVITIES**

### **CLINICAL TRIALS: Medical Monitor**

**Renew™ NCP-5 -1001** 02/19/2019 – 3/30/2022

*Renew Research, LLC*

A Randomized Pivotal Study of Renew™ NCP-5 for the Treatment of Mild Cognitive Impairment due to Alzheimer’s Disease or Mild Dementia of the Alzheimer’s Type

**EFC11570** 03/06/2013 – Dec 2017

*Sanofi*

Study to Evaluate the Effect of SAR236553 REGN727 on the Occurrence of Cardiovascular Patients Who Have Recently Experienced and Acute Coronary Syndrome (ODYSSEY-OUTCOMES)

### **CLINICAL TRIALS: Principal Investigator (Ongoing)**

**ISIS 678354-CS6**

2/29/24 – Ongoing

*Ionis Pharmaceuticals, Inc.*

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Olezarsen (ISIS678354) Administered Subcutaneously to Patients with Severe Hypertriglyceridemia (CORE 2)

**Defining Proteomic and Inflammatory Cell Phenotypes of Apheresis in Patients with Increased Lp(a) Levels.**

7/28/2023 – Ongoing

*University of Kansas Medical Center in Collaboration with Columbia University Irving Medical Center.*

The purpose of this study is to describe Lipoprotein(a), or Lp(a), its protein composition and cell types that are present in the blood of patients with high Lp(a) and increased inflammation before and after treatment with Lipoprotein Apheresis (LA).

**ISIS 678354-CS15**

5/19/2023 – Ongoing

*Ionis Pharmaceuticals, Inc.*

An Open-Label Extension study of Olezarsen (ISIS 678354) Administered Subcutaneously to Patients with Severe Hypertriglyceridemia (SHTG)

**ISIS 678354-CS9**

*Ionis Pharmaceuticals, Inc*

1/11/2023 – Ongoing

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Olezarsen (ISIS 678354) in Patients with Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease (Established or at Increased Risk for), or with Severe Hypertriglyceridemia. (ESSENCE)

**ISIS 678354-CS13**

5/24/2022 – Ongoing

*Ionis Pharmaceuticals, Inc.*

An Open-Label Extension Study of AKCEA-APOCIII-LRx Administered Subcutaneously to Patients with Familial Chylomicronemia Syndrome (FCS) (BALANCE)

**ISIS 678354-CS5**

8/12/2022 – Ongoing

*Ionis Pharmaceuticals, Inc.*

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of ISIS 678354 Administered Subcutaneously to Patients with Severe Hypertriglyceridemia (CORE)

**CTQJ230A12301**

2020 – Ongoing

*Novartis Pharmaceuticals*

A randomized double-blind, placebo-controlled, multicenter trial assessing the impact of lipoprotein(a) lowering with TQJ230 on major cardiovascular events in patients with established cardiovascular disease

**20180244**

*Amgen, Inc*

10/17/2022 – Ongoing

A Double-Blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Olpasiran on Major Cardiovascular Events in Patients with Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a)- OCEAN(a)

**AEGR-734-400***11/30/2017 – Ongoing**Aegerion Pharmaceuticals, Inc.*

MEASuRE: Metreleptin Effectiveness and Safety Registry

**CASCADE***08/05/2014 – Ongoing**FH Foundation*

CASCADE FH Registry Cascade Screening for Awareness and Detection of Familial Hypercholesterolemia

**CLINICAL TRIALS: Principal Investigator (Completed)***Sorted by Sponsor***Abbott Labs**

NA

04/23/2009 – 06/19/2009

Alternative Options to Minimize Niacin-Induced Flushing A Pilot Study.

**Acasti Pharma Inc**

ACA-CAP-002 (TRILOGY 2)

12/11/2018 – 4/2/2020

A Phase 3, Multi-center, Multi-national, Placebo-controlled, Randomized, Double-blind 26-week Study to Assess the Safety and Efficacy of CaPre® in Patients With Severe Hypertriglyceridemia

**Akcea Therapeutics, Inc**

ISIS 678354-CS2

06/06/2018 – 8/12/20

A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Phase 2 Study of ISIS 678354 Administered Subcutaneously to Patients with Hypertriglyceridemia and Established Cardiovascular Disease (CVD)

**Amarin Pharmaceuticals**

AMR-01-01-017

01/12/2010 – 06/20/2011

A Phase 3, Multicenter, Placebo Controlled, Randomized, Double Blind, 12 Week Study to Evaluate the Effect of Two Doses of AMR101 on Fasting Serum Triglyceride Levels in Patients With Persistent High Triglyceride Levels Despite Statin Therapy (ANCHOR)

**Amgen**

20170544

2020 – 10/5/2023

Amgen, Inc

A Phase 1, Randomized, Double-blind, Placebo-controlled, Single

Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 890 in Subjects With Elevated Plasma Lipoprotein(a)

Amgen 20210057

4/26/2022 – 7/20/2023

A Multicenter, Cross-sectional Study to Characterize the Distribution of Lipoprotein (a) Levels Among Patients with Documented History of Atherosclerotic Cardiovascular Disease (ASCVD)

20170625 11/4/2019 – transferred to Dr. Graves.  
A Double-blind, Randomized, Placebo controlled, Multicenter Study to Evaluate the Impact of Evolocumab on Major Cardiovascular Events in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke

20180109 2020 – 1/18/2023  
A Double-blind, Randomized, Placebo-controlled Phase 2 Study to Evaluate Efficacy, Safety, and Tolerability of AMG 890 (a GalNAc-conjugated Small Interfering RNA [siRNA]) in Subjects With Elevated Lipoprotein(a)

AMG 145 20120138 (Osler 2) 7/9/2015 – 8/2018  
A Multicenter, Controlled, Open-label Extension (OLE) Study to Assess the Long-term Safety and Efficacy of AMG 145 Open Label Study of Long-Term Evaluation Against LDL-C Trial

AMG 20120332 (GAUSS-3) 03/24/2014 – 05/2018  
Study of AMG 145 Compared With Ezetimibe in Hypercholesterolemic Subjects Unable to Tolerate an Effective Dose of an HMG-CoA Reductase Inhibitor Due to Muscle Related Side Effects (GAU11)

AMG 20140316 03/31/2016 – 03/14/2017  
A Randomized, Actively Controlled, Open-label, Multicenter Study of Efficacy and Safety of Evolocumab Compared With Low Density Lipoprotein Cholesterol (LDL-C) Apheresis, Followed by Single-Arm Evolocumab Administration in Subjects Receiving LDL-C Apheresis Prior to Study Enrollment

20110118 (FOURIER) 09/06/2012 – 2016  
Study Assessing the Impact of Additional LDL Cholesterol Reduction on Major Cardiovascular Events When AMG 145 is Used in Combination With Statin Therapy In Patients with Clinically Evident Cardiovascular Disease

Amgen 20130295 08/29/2016 – 6/22/2022  
A Multicenter, Open-label, Single-arm, Extension Study to Assess Long-term Safety of Evolocumab Therapy in Patients With Clinically Evident Cardiovascular Disease

## **Amylin**

2993-115 07/29/2002 – 08/29/2003  
A Phase 3, Randomized, Triple-Blind, Parallel-Group, Long-Term, Placebo-Controlled, Multicenter Study to Examine the Effect on Glucose Control (HbA1c)

of AC2993 Given Twice Daily in Subjects with Type 2 Diabetes Mellitus Treated with Metformin and a Sulfonylurea

2993-115E 03/20/2003 – 05/04/2006  
An Open-Label Extension Study of Protocol 2993-115 to Examine the Long-Term Effect On Glucose Control (HbA1c) and Safety and Tolerability of AC2993 Given Two Times a Day to Subjects Treated with Metformin and a Sulfonylurea.

#### **Astra-Zeneca**

OM-EPA-013 11/7/2014 – 09/10/2015  
A Randomized, Open-Label Crossover Study to Compare the Relative Bioavailability, Efficacy, and Safety of Epanova® and Lovaza® in Men and Women with a History of Pancreatitis.

#### **Aura Labs**

146-009 12/13/1999 – 09/05/2001  
A Dose-Response, Safety and Efficacy Study of Lovastatin XL in Adult Patients with Hypercholesterolemia.

146-011 04/25/2000 – 11/06/2001  
An Extended Safety, Efficacy and Tolerability Study of Lovastatin XL in Patients with Hypercholesterolemia.

#### **Aventis**

M100240/2002 03/13/2001 – 04/02/2002  
A Randomized, Double-blind, Comparator-controlled Trial to Evaluate the Pharmacodynamic Effects, Pharmacokinetics and Safety of M100240 in Subjects with Essential Hypertension Treated for 4 Weeks.

#### **B.Braun**

NA 1999 – 2010  
B. Braun, Melsungen, Germany  
Patient Registry for the H.E.L.P. System

LDLcAUS20406 07/24/2007 – 04/24/2009  
A Randomized Multicenter Crossover Study to Compare the Performance of the Plasma Futura Heparin Induced Extracorporeal LDL Precipitation (H.E.L.P.) Apheresis System to the Approved Plasma Secura H.E.L.P. Apheresis System in the Reduction of LDL Cholesterol

#### **Beijing-Peking University**

WPU-201 04/20/2011 – 05/06/2013

A Multi Center Double Blind Randomized Placebo Controlled Parallel Group  
Study of Lipid Lowering Effects of Xuezhikang in Patients with Hyperlipidemia

**Bristol-Myers Squibb**

CV137-022 11/17/1997 – 08/25/2000  
Open-Label, Long-Term Study of the Antihypertensive Activity and Safety of  
BMS-186716, A Dual Metalloprotease Inhibitor, in the Treatment of  
Hypertension

CV123-213 01/10/2000 – 05/27/2002  
A Double-Blind Randomized Study Comparing the Effects of a Modified Release  
Formulation of Pravastatin with Placebo and with Atorvastatin in Patients with  
Hypercholesterolemia

CV137-050 12/12/2000 – 12/12/2002  
Safety and Efficacy of Fixed Combination Metformin/Glipizide Products as First  
line Therapy in Patients with Type 2 Diabetes Mellitus Who have Inadequate  
Glycemic Control with Diet and Exercise

CV154-009 10/13/2000 – 04/02/2002  
A Double-blind Randomized, Placebo Controlled Study of the Efficacy and Safety  
of BMS-207940, a Selective Endothelin A Receptor Antagonist, in Subjects with  
Intermittent Claudication

CV137-119 02/13/2001 – 01/25/2002  
Nested Case-Controlled Study of Potential Risk Factors for Angioedema and  
Angioedema-Like Events in Subjects Previously Exposed to Omapatrilat

**Catabasis Pharmaceuticals**

CAT-200-201 08/09/2013 – 07/01/2014  
Pilot Study to Assess the Safety, Efficacy and Pharmacodynamics of CAT-2003  
Alone and in Combination with a Statin in Patients with Hyperlipidemia

CAT 2054-201 01/21/2016 – 07/14/2016  
A Randomized, Double-blind, Placebo Controlled study to Assess the Safety and  
Efficacy of CAT-2054 in Combination with Atorvastatin in Patients with  
Hypercholesterolemia

**Esperion Therapeutics**

ETC 1002-043 (CLEAR OUTCOMES) 2017 – 1/3/2023  
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Effects of  
Bempedoic Acid (ETC -1002) On the Occurrence of Major Cardiovascular Events

in Patients With, or At High Risk for, Cardiovascular Disease Who are Statin Intolerant

ETC 1002-008 02/11/2014 – 10/24/14  
Study to Evaluate the Efficacy and Safety of ETC-1002, Ezetimibe and the Combination in Hypercholesterolemic Patients with or without Statin Intolerance

### **Gemphire**

GEM-401 2017 – 2018  
A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects with Severe Hypertriglyceridemia (INDIGO-1)

### **Genzyme/ISIS**

ISIS301012-CS6 11/07/2008 – 11/12/2010  
A Randomized Double Blind Placebo Controlled Study to Assess Efficacy and Safety of ISIS 301012 as Add-on Therapy in Heterozygous Familial Hypercholesterolemia Subjects with Coronary Artery Disease

MIPO350018 03/11/2009 – 01/09/2011  
A Prospective Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Mipomersen in Patients with Severe Hypercholesterolemia on a Maximally Tolerated Lipid-Lowering Regimen and Who Are Not on Apheresis

ISIS 301012-CS6 10/30/2009 – 12/31/2014  
An Open-label extension Study to Assess the Long-Term Safety and Efficacy of ISIS 301012 in Subjects with Familial Hypercholesterolemia.

MIPO 38 01/25/2012 – 4/25/2016  
A Phase 3 Randomized Double-Blind Placebo Controlled Parallel Group Study to Assess the Safety and Efficacy of Two Different Regimens of Mipomersen in Patients with Familial Hypercholesterolemia

### **Ionis/Isis**

ISIS 304801-CS6 02/19/2015 – 02/5/2016  
The APPROACH Study: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of ISIS304801 Administered Subcutaneously to Patients with Familial Chylomicronemia Syndrome (FCS) 2/19/15-2/5/16

ISIS 304801-CS16 10/21/2015 – 03/15/2017  
The COMPASS Study: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of ISIS 304801 Administered Subcutaneously to Patients with Hypertriglyceridemia

ISIS 681257-CS6 2017 – 2019  
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Phase 2 Study of  
ISIS 681257 Administered Subcutaneously to Patients with  
Hyperlipoproteinemia(a) and Established Cardiovascular Disease (CVD)

ISIS 678354-CS3 2020 – 12/13/23  
Ionis Pharmaceuticals, Inc  
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of AKCEA-  
APOCIII-LRX Administered Subcutaneously to Patients with Familial  
Chylomicronemia Syndrome (FCS)(BALANCE)

### **Kaneka**

NA 2002 – 2008  
Kaneka Pharma America Corporation Patient Registry for the LIPOSORBER®  
LA-15 System.

NA 06/22/2007 – 05/25/2011  
LDL Apheresis for the Treatment of Congestive Heart Failure

Kaneka Medical America LLC 4/22/2024 – Ongoing  
A Multi-center Retrospective Chart Review of Atherosclerotic Cardiovascular  
Disease (ASCVD) Patients with Elevated Lipoprotein (a) (Lp(a)) Levels before  
and after being treated with Lipoprotein Apheresis (LA) using the Kaneka  
LIPOSORBER® LA-15 System in the U.S.

### **Kos Pharmaceuticals**

019-02-03-CR 06/17/2004 – 09/14/2007  
OCEANS: An Open-Label Evaluation of the Safety and Efficacy of a  
Combination of Niacin ER and Simvastatin in Patients with Dyslipidemia  
(OCEANS)

### **Kowa**

K-877-302 2017 – 11/15/2022  
Kowa Research Institute, Inc  
Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in  
Patients with Diabetes (PROMINENT)

NA 11/10/2011 – 07/01/2014  
A Study Comparing the Effects of Pitavastatin, Atorvastatin and Rosuvastatin on  
Plasma Levels of CoQ10 (SPARQ)

### **Merck Inc**

ZOC465 07/27/1999 – 08/16/2000

A Multi-center, Open Label Study To Evaluate Simvastatin 20, 40 and 80 mg in Patients with Coronary Heart Disease

MK0767/006-00 07/11/2000 – 01/25/2002

A Multicenter, Double-Blind, Randomized, Placebo- and Active-Comparator-Controlled, Parallel Study to Evaluate the Glucose-Lowering Efficacy, Lipid-Altering Efficacy, Safety, and Tolerability of L-410198 in Patients with Type 2 Diabetes Mellitus

MK0767/012 01/02/2002 – 03/27/2003

A Multicenter, Double-blind, Randomized, Placebo-and Active Controlled, Parallel Study to Evaluate the Glucose and Lipid-Altering Efficacy and Safety of L-410918 in Patients With Type 2 Diabetes.

051-00 10/20/2003 – 05/04/2006

A Multicenter, Double-Blind, Randomized, Parallel Group, 6-Week Study to Evaluate the Efficacy and Safety of Ezetimibe/Simvastatin Combination Tablet Versus Atorvastatin in Patients with Hypercholesterolemia

058 07/06/2004 – 11/09/2006

A Multicenter, Randomized, Double-Blind Study to Evaluate the Lipid-Altering Efficacy and Safety of the Ezetimibe/Simvastatin Combination Tablet Versus Rosuvastatin in Patients with Primary Hypercholesterolemia

015-05 9/2023 – 8/2024

A Phase 3 Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of MK-0616 in Reducing Major Adverse Cardiovascular Events in Participants at High Cardiovascular Risk

## **Novartis**

CDJN608B/2302 10/22/2002 – 02/16/2011

A Multinational, Randomized, Double-Blind, Placebo-Controlled, Forced-Titration, 2x2 Factorial Design Study of the Efficacy and Safety of Long-Term Administration of Nateglinide and Valsartan in the Prevention of Diabetes and Cardiovascular Outcomes

CPJMR32103 03/11/2011 – 02/06/2013

An Observational Biomarker Study to Characterize PCSK9 Concentrations and Cholesterol Profiles in Patients Eligible for LDL Apheresis

ACZ885M2301 12/20/2012 – 7/22/2019

A Randomized Double-Blind Placebo Controlled Event Driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post Myocardial Infarction Patients With Elevated hsCRP (CANTOS)

CTQJ230A12001 07/05/2019 – 10/12/2021  
Multi-center cross-sectional epidemiological study to characterize the prevalence and distribution of lipoprotein(a) levels among patients with established cardiovascular disease

**Parke-Davis**

1011-047 03/27/2000 – 04/05/2001  
A Randomized, Double-Blind, Parallel-Arm, Dose-Dependent, Multicenter Study to Evaluate the Effects of Avasimibe on Endothelial Function Using Brachial Artery Ultrasound in Patients with Atherosclerotic Vascular Disease

**Pfizer Inc**

1011 06/04/2001 – 07/25/2002  
A 16-Week, Double-Blind, Multicenter Study to Evaluate the Effect of Avasimibe in Combination with Atorvastatin on Lipids in Patients with Type IIa and IIb Dyslipidemia

1027-018 10/10/2001 – 10/29/2002  
An 8-week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study in Hypercholesterolemic patients to Determine the Efficacy and Safety of Combination Therapy With CI-1027 and a Statin (Protocol)

B1481020 06/27/2014 – 08/22/2016  
Study to Assess The Efficacy Long Term Safety and Tolerability of PF-04950615 In Subjects With Primary Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events

Pfizer B1481030 01/6/2015 – 01/19/2016  
A Phase 3, Double-Blind, Double-dummy, Randomized, Placebo and Active Controlled, Parallel-group Study to Assess the Efficacy, Safety and Tolerability of pf-04950615 in Subjects with Dyslipidemia who are Intolerant to Statins

Pfizer 1022/38 (SPIRE 1 &2) 11/1/2015 – June 2017  
B1481022 - Phase 3 Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (PF-04950615; RN316), In Reducing The Occurrence Of Major Cardiovascular Events In High-Risk Subjects – SPIRE 1  
B1481038 - Phase 3 Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (PF-04950615; RN316), In Reducing The Occurrence Of Major Cardiovascular Events In High-Risk Subjects – SPIRE 2

**PPD Development**

2002-002 12/16/2004 – 11/09/2006

A double-blind, randomized, dose-escalating efficacy and safety study of Implitapide at daily doses of 10mg, 15 mg, 20 mg, 25mg,35 mg, and 40mg compared with placebo in patients with heterozygous familial hypercholesterolemia (HeFH)

2002-003 12/16/2004 – 11/09/2006  
An open-label, dose-escalating efficacy and safety study of Implitapide at daily doses of 10mg, 15 mg, 20 mg, 25mg, 30mg, 35 mg, and 40mg in patients with hypertriglyceridemia (HTG) on maximal, concurrent triglyceride-lowering therapy

### **Regeneron**

R727-CL-1003 03/17/2011 – 06/19/2012  
A Randomized Double-Blind Placebo Controlled 12 Week Study of the Safety and Efficacy of REGN727 in Patients with Heterozygous Familial Hypercholesterolemia

R727-CL-1032 05/11/2012 – 5/15/2015  
Extension of Study R727-CL-1003 to Evaluate the Long-Term Safety and Efficacy of REGN727 Administered by Subcutaneous Injection in Patients with Heterozygous Familial Hypercholesterolemia

R727-CL-1308 02/19/2014 – 8/10/2015  
Study to Evaluate the Efficacy and Safety of an Every Four Weeks Treatment Regimen of Alirocumab in Patients with Primary Hypercholesterolemia (CHOICE)

R727-CL-1216 02/04/2015 – 06/27/2016  
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate The Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia Undergoing Lipid Apheresis Therapy (ESCAPE) \*  
Highest enrolling site

R727-CL-1119 11/19/2012 – 03/03/2017  
A Randomized, Double-Blind, Double-Dummy, Active-Controlled Study to Evaluate the Efficacy and Safety of REGN727/SAR236553 in Patients with Primary Hypercholesterolemia Who Are Intolerant to Statins.

NA 09/20/2016 – 02/2017  
Regeneron Pharmaceuticals Alirocumab and LDL-Apheresis: Potential to Decrease Apheresis Treatment in Patient with Heterozygous Familial Hypercholesterolemia or in Those at High Risk of CV Events Due to High LDL Level.

R1500-CL-1522 08/03/18 – 9/9/20

Regeneron Pharmaceuticals, Inc.  
A Phase 2, Randomized, Placebo-Controlled Study of Safety and Efficacy Following Repeat-Dose Administration of Evinacumab (Anti-ANGPTL3) in Patients with Severe Hypertriglyceridemia (sHTG) at Risk for Acute Pancreatitis

R1500-CL-1643 02/05/2018 – 4/15/2021

Regeneron Pharmaceuticals, Inc.  
A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Varying Doses and Dose Regimens of Evinacumab in Patients with Persistent Hypercholesterolemia Despite Maximally Tolerated Lipid Modifying Therapy.

R1500-CL-17100 2020 – 2022

Regeneron Pharmaceuticals, Inc  
A Three-Part, Single-Arm, Open-Label Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Evinacumab in Pediatric Patients with Homozygous Familial Hypercholesterolemia.

R1500-HTG-20118 5/17/2022 – 4/27/2023

Regeneron Pharmaceuticals.  
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Evinacumab in Patients with Severe Hypertriglyceridemia for the Prevention of Recurrent Acute Pancreatitis.

### **Renew**

Renew™ NCP-5 -1001 02/19/2019 – 2/7/2022

A Randomized Pivotal Study of Renew™ NCP-5 for the Treatment of Mild Cognitive Impairment due to Alzheimer’s Disease or Mild Dementia of the Alzheimer’s Type.

### **Roche/Hoffman-LaRoche**

NR15534-M4419 05/18/1998 – 08/08/2001

A Prospective, open-label, randomized, parallel group, multicenter study to assess the pharmaco-economic and medical outcomes in patients with community-acquired pneumonia treated with a practice guideline recommending early hospitalization.

NR15682C/M37049 12/02/1998 – 12/01/2000

Evaluate the Efficacy of Orlistat Plus Diet in Obese Hypertensive Patients Inadequately Controlled with Antihypertensive Medication(s)

NR15804/M37048 12/02/1998 – 12/01/2000

A 52-Week, Multicenter, Randomized, Double Blind, Placebo Controlled Study of the Efficacy of Orlistat Treatment Plus Diet in Obese Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy

WV15671 02/02/1999 – 06/23/2000  
A randomized, double-blind, placebo-controlled, multicenter study of efficacy based on the time to treatment of influenza infection with the neuraminidase inhibitor R0 64-0796 (also known as GS 4104)

## Sanofi

EFC4736 12/28/2001 – 12/31/2003  
A randomized, Double Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose, Multicenter Study of weight-reducing Effect and Safety of SR141716 in Obese Patients with Type 2 Diabetes

EFC5826 05/25/2006 – 08/23/2010  
Randomized, Multinational, Multicenter, Double-Blind, Placebo-Controlled, Two-Arm Parallel Group Trial of Rimonabant 20 mg OD for Reducing the Risk of Major Cardiovascular Events in Abdominally Obese Patients with Clustering Risk Factors (CRESCENDO)

EFC6909 09/22/2008 – 05/12/2009  
12-month, placebo-controlled, parallel group, fixed-dose study to evaluate the efficacy and safety of AVE5530 25mg-day and AVE5530 50 mg-day in patients with primary hypercholesterolemia

EFC6017 01/30/2009 – 06/30/2011  
A randomized, double-blind, placebo-controlled, 2-arm parallel-group, multicenter study with a 24-week main treatment period and an extension assessing the efficacy and safety of AVE0010 on top of pioglitazone in patients with type 2 diabetes not adequately controlled with pioglitazone

EFC12492 10/09/2012 – 03/11/2015  
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of SAR236553/REGN727 in Patient with Heterozygous Familial Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy.

LTS11717 12/16/2012 – 03/05/2015  
Long Term Safety and Tolerability of REGN727/SAR236553 in High Cardiovascular Risk Patients with Hypercholesterolemia not Adequately Controlled with Their Lipid Modifying Therapy: A Randomized Double Blind Placebo Controlled Study.

CUP14366 07/21/2015 – 06/28/2016

Alirocumab Expanded Access Program for the Treatment of Patients with Severe Hypercholesterolemia not Controlled with Maximal Tolerated Dose of Lipid-Lowering Therapy Administered According to Standard of Care

LTS13463 12/13/2013 – Oct 2017  
Open Label Extension Study of EFC12492, R727-CL-1112, EFC12732 and LTS11717 Studies to Assess the Long-Term Safety and Efficacy of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia

EFC11570 03/06/2013 – Dec 2017  
Study to Evaluate the Effect of SAR236553 REGN727 on the Occurrence of Cardiovascular Patients Who Have Recently Experienced and Acute Coronary Syndrome (ODYSSEY-OUTCOMES)

### **Takeda Pharmaceuticals**

TAK475-021 02/08/2006 – 02/03/2009  
A Double-Blind, Randomized Study to Evaluate the Efficacy and Safety of TAK-475 100 mg or Placebo When Co-Administered With High Dose Statin Therapy in Subjects With Primary Hypercholesterolemia  
Major Goals:

TAK475-021 02/08/2006 – 10/02/2007  
A Double-blind, Randomized Study to Evaluate the Efficacy and Safety of Tak-475 50 mg, 100 mg or Placebo When Co-Administered with Rosuvastatin 10mg or 20 mg in Subjects with Primary Hypercholesterolemia

**University of California San Diego (UCSD)/Kaneka** 6/18/2021 – 4/21/2025  
Defining the Inflammatory Monocyte and Cytokine Changes Associated with Lipoprotein Apheresis in Patients with Elevated Lipoprotein(a)

### **University of Pennsylvania/RegenXBio**

FHGT002 02/03/2017 – 11/4/2020  
AAV8-mediated Low Density Lipoprotein Receptor (LDLR) Gene Replacement in Subjects with Homozygous Familial Hypercholesterolemia (HoFH)

### **Zydus**

SARO.15.001 2017 – 2017  
A Multicenter, Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel Arm, 12-week Study to Evaluate the Safety and Efficacy of Saroglitazar Magnesium 1, 2, and 4mg in Patients with Fasting Triglyceride  $\geq 500$ mg/dL and  $\leq 1500$ mg/dL.

### **CLINICAL TRIALS: Sub-Investigator (Completed)**

Efficacy of Almonds added to Chronic Statin Therapy 2008 – 2012

Funding Source: Almond Board  
Principal Investigator: Janelle Ruisinger, PharmD  
Co-Investigator: Patrick M. Moriarty, MD; Jim Backes PharmD

Safety and Efficacy of Policosanol added to Chronic  
Statin Therapy: a Pilot Study. 2006 – 2010  
Funding Source: MarcOR and General Research Fund  
(University of Kansas School of Pharmacy)  
Principal Investigator: Jim Backes, Pharm D  
Co-Investigator: Patrick M. Moriarty, MD

(Study Drug) and its Effect on Inflammatory Markers 2002 – 2003  
Funding Source: Abbott  
Principal Investigator: James Backes, PharmD  
Co-Investigators: Patrick M. Moriarty, MD; Cheryl Gibson, PhD,  
Jared Calish, PharmD

Skin Thickness in Patients with Scleroderma 2000 – 2004  
Funding Source: internal  
Co-Investigator: Patrick M. Moriarty, MD, Daniel  
Stechschulte, MD, Ahmed Samad, MD

Evaluate the use of blood viscosity as a predictor for  
adverse events associated with Intravenous  
Immunoglobulin (IVIg) infusion 2004  
Funding Source: internal  
Principal Investigator: Daniel J. Stechschulte, MD  
Sub-Investigator: Patrick M. Moriarty, MD, Padmaja  
Adusumilli, MD, Ryan Sullivan, MD

Vasoreactivity and Endothelial Function in Neonates  
of Cigarette Smoking Mothers 2000 – 2001  
Funding Source: internal  
Co-Investigator: Patrick M. Moriarty, MD, Leone Mattioli, MD

### **RESEARCH: Grants**

Title of Grant: The John A. Hartford Foundation Award  
Funding Source: The John A. Hartford Foundation  
Principal Investigator: Patrick M. Moriarty, MD  
Years: 1998-2000

Title of Grant: Primary Care Physicians Education Grant  
Funding Source: Primary Care Physicians Education Grant  
Principal Investigator: Patrick M. Moriarty, MD

Years: 1998-2000

Title of Contract: Doppler Vasoreactivity and IMT Measurements

Funding Source: Hewlett-Packard and Agilent Technologies

Principal Investigator: Patrick M. Moriarty, MD

Years: 2000-2002

Title of Grant: Blood Viscosity Changes following HELP

Funding Source: Rheologics, Inc.

Principal Investigator: Patrick M. Moriarty, MD

Years: 2000-2002

Title of Grant: Serum hsCRP Changes following HELP

Funding Source: Abbott Laboratories

Principal Investigator: Patrick M. Moriarty, MD

Years: 2000-2001

Title of Grant: Serum Lp-PLA2 Changes following HELP

Funding Source: Diadexus

Principal Investigator: Patrick M. Moriarty, MD

Years: 2001 – 2002

Title of Grant: Serum Pro-inflammatory-HDL Changes following HELP

Funding Source: UCLA

Principal Investigator: Patrick M. Moriarty, MD

Years: 2004-2005

Title of Grant: NMR Lipoprofile Changes following HELP

Funding Source: Liposcience

Principal Investigator: Patrick M. Moriarty, MD

Years: 2004-2005

Title of Grant: Oxidized-LDL Changes following HELP

Funding Source: UC-SD

Principal Investigator: Patrick M. Moriarty, MD

Years: 2005

### **PUBLICATIONS: Editorials, Book Chapters, & Others**

1. **Moriarty PM**. Lipoprotein-Associate Phospholipase A2: Effects of Low Density Lipoprotein Apheresis. Home of the International Atherosclerosis Society, 2005 Dec (Commentary)
2. **Moriarty PM**. Balancing Statin Risk and Benefit. *Heart-Health Alliance*, May 2005 (Monograph)

3. **Moriarty PM**, Backes J, Gibson CA. What is familial hypercholesterolemia and how should it be treated? *Clinical Challenges in Lipid Disorders* 2008 (pp. 219-233). Clinical Publishing, Oxford. (Book Chapter)
4. **Moriarty PM**, Gibson CA, Flechsenhar K. Familial hypercholesterolemia and lipid apheresis. In *Therapeutic Lipidology* 2007 (pp. 267-289). Humana Press. (Book Chapter)
5. **Moriarty PM**. “LDL-apheresis” *Clinical Lipidology: A Companion to Braunwald's Heart Disease*. Saunders/Elsevier. (Book Chapter)
6. **Moriarty PM**, Santos RD. “Special Patient Populations: Familial Hypercholesterolemia and Other Severe Hypercholesterolemias” *Clinical Lipidology: A Companion to Braunwald's Heart Disease* 2<sup>nd</sup> ed. Saunders/Elsevier. 2015. pg 440-453. (Book Chapter)
7. **Moriarty PM**, Hemphill L. Lipoprotein apheresis. *Cardiology clinics*. 2015 May 1;33(2):197-208. (Book Chapter)
8. **Moriarty PM**, McCalley AE. Lipid-Lowering Therapy and Apheresis: Indications and Outcomes. In *Combination Therapy In Dyslipidemia* 2015 (pp. 143-152). Adis, Cham. (Book Chapter)
9. **Moriarty PM**. Large Clinical Trials of Statin-Associated Muscle Symptoms. In *Statin-Associated Muscle Symptoms* 2020 (pp. 63-70). Springer, Cham. (Book Chapter)
10. **Moriarty PM**. Special Patient Populations: Familial Hypercholesterolemia and other severe Hypercholesterolemias. Pg 320-335 (Book Chapter). *Clinical Lipidology: A companion to Braunwald's heart disease*. 3<sup>rd</sup> ed. Philadelphia, PA: El Sevier – Health Sciences Division; 2023.
11. **Moriarty PM**. Thrombosis, Inflammation, and Lipoprotein(a): Clinical Implications. Pg 189-206 (Book Chapter). Kostner K, Kostner GM, Toth PP, editors. *Lipoprotein(A)*. 1<sup>st</sup> ed. Cham, Switzerland: Springer International Publishing; 2023.

## **PRESENTATIONS**

### **PRESENTATIONS: Lectures & Keynote Addresses**

1. **Moriarty PM**, Gibson, CA. A Familial Hypercholesterolemic Patient Treated with Heparin-Induced Extracorporeal LDL Precipitation (HELP). Presented to National Lipid Education Council, February 8, 2002.
2. **Moriarty PM**, Gibson CA "Heparin-induced Extracorporeal LDL Precipitation (HELP) Therapy and its Effect on Whole Blood Viscosity”, B Braun Medical, Bad

- Oeynhausen, Germany, February 1-2, 2003.
3. **Moriarty PM.** Diagnosis and treatment of abnormal cholesterolemia in the diabetic patient including the metabolic syndrome patient. Saturday Morning at KU Med. Chicken Soup for diabetes Mellitus or Everything You Want to Know and Ask About Diabetes Mellitus, 2005.
  4. **Moriarty PM.** Diabetic Lipid Management: How low should we go? The Ultimate Summit for Primary Care: Innovations in Neurology, Diabetes, and Infectious Disease, Kansas City, MO, 2005.
  5. **Moriarty PM.** Atherosclerosis and its association with hemorheology. Continuing Medical Education, Weekly Cardiovascular Conference, St. Luke's Hospital, Kansas City, MO, 2005.
  6. **Moriarty PM.** Novel CV Risk Factors. Preventive Cardiology 2005: A Checklist for the Primary Care Physician, Kansas City, Missouri, June, 2005
  7. **Moriarty PM.** LDL Apheresis and the treatment of Familial Hypercholesterolemia (FH). Midwest Lipid Association, Chicago, Illinois, July, 2005.
  8. **Moriarty PM.** "Omega-3 Fatty Acids and Their use in the Prevention of Cardiovascular Disease." Grand Rounds, Kansas University Medical Center, August 16, 2006.
  9. **Moriarty PM.** Lipid and non-lipid pleiotropic effects of apheresis. Midwest Lipid Association Annual Meeting, Kansas City, MO, October 22, 2006.
  10. **Moriarty PM.** PPAR's, Adiponectin and Cardiovascular Disease. Kansas City Veteran's Administration Conference, Kansas City, MO, October 27, 2006.
  11. **Moriarty PM.** Apheresis Therapy for Coronary Artery Disease. 6<sup>th</sup> World Congress of the International Society for Apheresis and World Apheresis Association 11<sup>th</sup> Congress, Yokohama, Japan, March 3, 2007.
  12. **Moriarty PM.** "LDL-Apheresis: Current and Future Utilization of Vascular Diseases." Grand Rounds, Kansas University Medical Center, April 4, 2007.
  13. **Moriarty PM.** "Update on Atherosclerosis and the Prevention of Vascular Disease." Grand Rounds, Kansas University Medical Center, August 15, 2007.
  14. **Moriarty PM.** Update: The Vascular Benefits of Omega-3 Fatty Acids. Preventive Cardiology in Primary Care, Topeka, KS, October 19, 2007.

15. **Moriarty PM**. Endothelium/Vessel/Microcirculation. Apheresis and Dialysis Conference 2007, Berlin Germany, December 6, 2007.
16. **Moriarty PM**. Update on LDL-apheresis in the US. 2009 WAA/ISFA Joint Congress, Buenos Aires, Argentina, March 19, 2009.
17. **Moriarty, PM**. “Interdisciplinary Research in a Clinical Setting: The Use of Multiple Disciplines in the Atherosclerosis and LDL-Apheresis Center.” Grand Rounds, Kansas University Medical Center, January 13, 2010.
18. **Moriarty PM**. Dyslipidemia and the Metabolic Syndrome in the Obese Patient. The University of Kansas Hospital Multidisciplinary Management of Obesity: The Twenty- First Century Pandemic, Overland Park Convention Center, May 22, 2010.
19. **Moriarty PM**. Biological Effects of Lipid Apheresis. ASAIO (American Society for Artificial Internal Organs) 56<sup>th</sup> Annual Conference. Hilton Inner Harbor, Baltimore, Maryland, May 25, 2010.
20. **Moriarty PM**, Luyendyk JP, Gibson CA, Backes JM. Effect of low-density lipoprotein apheresis on plasma levels of apolipoprotein e4. EPS Global 1<sup>st</sup> International Heart Forum, Beijing, China, August 14, 2010.
21. **Moriarty PM**. “Hemorheology: Its Effects on Cardiovascular and Cerebrovascular Diseases.” Grand Rounds, Kansas University Medical Center, October 29, 2010.
22. **Moriarty PM**. “LDL-Apheresis using Dextran Sulfate Absorption and Heparin Precipitation”. American Society for Apheresis 2011 Annual Meeting, Scientific Symposium: Special Apheresis Therapies, Scottsdale, Arizona, June 3, 2011.
23. **Moriarty PM**, Backes J, Ruisinger J. “Interdisciplinary Research in a Clinical Setting: ‘From Fruits to Nuts,’ Alternative Methods in Treating Atherosclerosis and Dyslipidemia.” Grand Rounds, Kansas University Medical Center, August 8, 2011.
24. **Moriarty PM**. “Association of ApoE and HDL-C with Cardiovascular and Cerebrovascular Disease: Potential Benefits of LDL-Apheresis Therapy”. ISFA Vienna – 8<sup>th</sup> Annual International Society for Apheresis Congress, Vienna, Austria, September 15, 2011.
25. Underberg J, Brinton E, McGowan, M, **Moriarty PM**. Expert Roundtable: Familial Hypercholesterolemia. The Medical Roundtable: Cardiovascular Edition

- (2012).
26. **Moriarty PM.** “The Role of Apheresis in the Management of FH”. 2012 National Lipid Association (NLA) Spring Clinical Lipid Update. San Diego, CA, March 11, 2012.
  27. **Moriarty PM.** “Lipoprotein Apheresis and HDL”. Dresden International Symposium on Therapeutic Apheresis. Dresden, Germany, March 15, 2012.
  28. **Moriarty PM.** “Liposorber for LDL apheresis”. Canadian Apheresis Group Annual General Meeting. Toronto, Canada, April 14, 2012.
  29. **Moriarty PM.** “Biomechanical Stress: Its Association with Atherosclerosis and Cardiovascular/ Cerebrovascular Disease.” Grand Rounds, Kansas University Medical Center, November 14, 2012.
  30. **Moriarty PM.** “Prevention: LV, Vascular and Lipoprotein Function: Effect of LDL- Apheresis on HDL-C Functionality.” San Francisco, California, March 10, 2013.
  31. **Moriarty PM.** “Update on Research Related to Atherosclerosis and Dyslipidemia.” Grand Rounds, Kansas University Medical Center, March 13, 2013.
  32. **Moriarty PM.** “Biomechanical Stress and its Association to Atherosclerosis. Hangzhou, China, May 9, 2013.
  33. **Moriarty PM.** “Peripheral Arterial Disease and Apheresis. Hangzhou, China, May 9, 2013.
  34. **Moriarty PM.** “FH and Present-Day Management: *Why is this Disease Vital to Treat.*” 2013 National Lipid Association (NLA) Spring Clinical Lipid Update. Las Vegas, NV March 30, 2013.
  35. **Moriarty PM.** “Rheological Implications of Apheresis in FH. 2013 National Lipid Association (NLA) Spring Clinical Lipid Update. Las Vegas, NV March 30, 2013.
  36. **Moriarty PM.** “Lipoprotein(a) and the Risk of Cardiovascular Disease: Pathophysiology, diagnosis, and treatment. Hangzhou, China, May 10, 2013.
  37. **Moriarty PM.** “Effect of Acute Cholesterol Lowering on Lipoprotein”. Dresden International Symposium on Therapeutic Apheresis. Dresden, Germany, March 14, 2014.

38. **Moriarty PM.** “Lp(a) as a target”. National Lipid Association. Orlando, Florida. Friday, May 2, 2014.
39. Vaishnav N, **Moriarty PM.** “Utility of Detecting and Testing Hyperuricemia in High-Risk Patients with Unexplained Chest Pain: A case report. June 6, 2014.
40. **Moriarty PM.** “The Present Treatment of Elevated Lp(a) and CVD Prevention: Lipid Apheresis”. 9<sup>th</sup> Lipid Club and Therapeutic Apheresis. Rome, Italy. June 6, 2014.
41. **Moriarty PM.** “Decision Making in Medication Based Prevention of Coronary Artery Disease in the Era of Multiple Guidelines”. 1 Annual Summit of Cardiovascular Diseases: ACC Kansas Chapter. Kansas City, KS. October 4, 2014.
42. **Moriarty PM.** “Advanced Approaches for Optimizing Outcomes in the Severe FH Patient”. Cardio Metabolic Health Congress. Boston, Massachusetts. October 23, 2014.
43. **Moriarty PM.** “Efficacy and Safety of the Proprotein Convertase Subtilisin/kexin Type 9 Monoclonal Antibody, Alirocumab, versus Ezetimibe, in Patients with Statin Intolerance as Defined by a Placebo Run-in and Statin Rechallenge Arm”. American Heart Association. Chicago, Illinois. November 17, 2014.
44. **Moriarty PM.** “Lipid Apheresis for elevated Lp(a)”. World Congress of Lipidology. Vienna, Austria. December 6, 2014.
45. **Moriarty PM.** “Statin Intolerance: Therapeutic Options”. World Congress of Lipidology. Vienna, Austria. December 6, 2014.
46. **Moriarty PM.** “Treatment of Dyslipidemia and Atherosclerosis”. Cardiology Update. Carondelet Heart Institute. Kansas City, MO. April 24, 2015.
47. **Moriarty PM.** “PCSK9 Inhibitors for Patients with Statin Intolerance (Alternative Trial), FH Patients Receiving Lipoprotein Apheresis (Escape Trial)”. International Society for Apheresis Congress. May 15, 2015.
48. **Moriarty PM.** “Rheological Improvement in Lipid Apheresis – More Than A PleiotropicEffect?” International Society for Apheresis Congress. Cancun, Mexico. May 15, 2015.
49. **Moriarty PM.** “Evaluating Residual Risk and Long-Term Management of the Young CHD Patient”. National Lipid Association. Chicago, Illinois. June 14,

- 2015.
50. **Moriarty PM.** “Statin Intolerance and PCSK9 Inhibitors”. Heartland AACE. Kansas City, Kansas. August 22, 2015
  51. **Moriarty PM.** “FH Cascade Registry”. FH Global Summit. FH Foundation. Pasadena, California. September 25, 2015.
  52. **Moriarty PM.** “Lipid Apheresis and Statin Therapy”. Cardiac Nurses Symposium. Kansas City, KS. October 6, 2015.
  53. **Moriarty PM.** “Special Considerations in Familial Hypercholesterolemia”. Cardiometabolic Health Congress. Boston, Massachusetts. October 22, 2015.
  54. Brown WV, **Moriarty PM.** McKenney JM. JCL Roundtable: PCSK9 Inhibitors in Clinical Practice. NLA PCSK9 Roundtable. Orlando, Florida. November 6, 2015.
  55. Brown WV, **Moriarty PM.** Remaley AT, Tsimikas S. “JCL Roundtable: Should We Treat Elevations in Lp(a)?” NLA Lp(a) Roundtable. Orlando, Florida. November 6, 2015.
  56. **Moriarty PM.** “Present and Future Therapies for HoFH Patients”. NLA Masters Summit. Orlando, Florida. November 7, 2015.
  57. **Moriarty PM.** “The ODYSSEY ESCAPE trial: rationale, design and patient characteristics at baseline” Dresden International Symposium on Therapeutic Apheresis. Dresden, Germany. March 17, 2016.
  58. **Moriarty PM.** “Inflammatory and ApoE4-bound HDL pre and post apheresis” Dresden International Symposium on Therapeutic Apheresis. Dresden, Germany. March 19, 2016.
  59. **Moriarty PM.** “Update on the Treatment of Atherosclerosis” Kansas City Southwest Clinical Society. St. Joseph Medical Center. Kansas City, MO. May 2, 2016
  60. **Moriarty PM.** “Effectiveness of Mipomersen compared to Alirocumab for Heterozygous Familial Hypercholesterolemia” Symposium of the International Atherosclerosis Society. St. Petersburg, Russia. June 3, 2016.
  61. **Moriarty PM.** “Clinical Pharmacology: Omega-3- Index” Lunch N’ Learn. University of Kansas Medical Center. August 10, 2016.

62. **Moriarty PM.** “Effect of Alirocumab on the frequency of Lipoprotein Apheresis: a randomized Phase III trial” European Society of Cardiology Congress. Rome, Italy. August 29, 2016.
63. **Moriarty PM.** “Biomechanical Stress and its Association with Atherosclerosis” New York University Grand Rounds. New York, NY. October 7, 2016.
64. **Moriarty PM.** “Update on the Treatment of Atherosclerosis” Kansas City Southwest Clinical Society's 94th Annual Fall Clinical Conference. Overland Park, KS. October 28, 2016.
65. **Moriarty PM.** “Trials of PCSK9 Inhibitors in Statin-Intolerant Patients: What Have We Learned?” AHA Scientific Sessions. New Orleans, LA. November 15, 2016.
66. **Moriarty PM.** “Update on the Present and Future Treatment of Atherosclerosis” NKC Hospital Grand Rounds. Kansas City, MO. December 7, 2016.
67. **Moriarty PM.** “Update on Atherosclerosis and Cardiovascular Disease” University of Kansas Medical Center Grand Rounds. Kansas City, KS. December 14, 2016.
68. **Moriarty PM.** “Odyssey Alternative” Statin Associated Muscle Afflictions Building Forum. Washington DC. January 13, 2017.
69. **Moriarty PM.** “Recent Lp(a) Apheresis Trials: Implications for Clinicians”. 3rd World Congress on Clinical Lipidology. Brisbane, Australia. February 11, 2017.
70. **Moriarty PM.** “Apheresis and Other Therapies”. 3rd World Congress on Clinical Lipidology. Brisbane, Australia. February 11, 2017.
71. **Moriarty PM.** “Lp(a) and its Association with CVD, CVA and Aortic Stenosis”. NLA Clinical Update. Phoenix, AZ. February 25, 2017.
72. **Moriarty PM.** “Novel Drug Therapies for the Treatment of Hypercholesterolemia”. 11 International Society for Apheresis Congress. Copenhagen, Denmark. May 18, 2017.
73. **Moriarty PM.** “Update on Lipoprotein Apheresis Therapy”. 11th International Society for Apheresis Congress. Copenhagen, Denmark. May 19, 2017.
74. **Moriarty PM.** “ESCAPE to the Real World: A Retrospective Review of Clinical Use of Alirocumab in Lipoprotein Apheresis Patients”. ICCAD. Venice, Italy.

October 15, 2017.

75. **Moriarty PM.** “A 13-year-old male with stroke has normal lipid profile, no cardiac defects and a lipoprotein a level of 410” Clinical significance of Lp(a) in youth & role of imaging in atherosclerosis” American Heart Association Scientific Sessions. Anaheim, CA. November 12, 2017.
76. **Moriarty PM.** “The Important Role of Lipoprotein(a) in Cardiovascular Disease: Present and Future Therapeutic Options”. Academic CME. Anaheim, CA. November 12, 2017.
77. **Moriarty PM.** “Microvascular CVD Aspect of Diabetes and its Association with Rheology” 2018 Emirates Diabetes and Endocrine Congress. Dubai, UAE. Friday, March 2, 2018.
78. **Moriarty PM.** “Diabetic Dyslipidemia: Effective Management Reduces Cardiovascular Risk” 2018 Emirates Diabetes and Endocrine Congress. Dubai, UAE. Friday, March 2, 2018.
79. **Moriarty PM.** “Statin Intolerance” 2018 Emirates Diabetes and Endocrine Congress. Dubai, UAE. Saturday, March 3, 2018.
80. **Moriarty PM.** “Present and Future Therapy” University of Missouri School of Medicine, Division of Cardiovascular Medicine, Grand Rounds. Columbia, MO. March 15, 2018.
81. **Moriarty PM.** “Treating Lipoprotein(a)-hyperlipoproteinemia and Progressive Cardiovascular Disease with Lipoprotein Apheresis in North America”. 2<sup>nd</sup> Congress of European ISFA. Vienna, Austria. March 23, 2018.
82. **Moriarty PM.** Present and Future Therapy for Elevated Lp(a) and the Reduction of CVD. National Lipid Association Scientific Sessions. Las Vegas, NV. April 28, 2018.
83. **Moriarty PM.** Update on Lipid Therapy and CVD Prevention. 15th Annual Rocky Mountain Metabolic Syndrome Symposium. Denver, CO. Friday, May 4, 2018.
84. **Moriarty PM.** Challenging Lipid Cases. 15th Annual Rocky Mountain Metabolic Syndrome Symposium. Denver, CO. Friday, May 4, 2018.
85. **Moriarty PM.** Debate – Pro: Lipoprotein(a) – Should be Measured in all Patients at Higher CVD Risk. ASPC Congress on Cardiovascular Disease Prevention. Bernalillo, NM. Sunday, July 29, 2018.

86. **Moriarty PM**. Blood Flow and Vascular Disease: Foundation for the External Counter Pulsation Trial for Mild Cognitive Impairment and Alzheimer's Disease. University of Kansas Medical Center. Department of Internal Medicine-Grand Rounds. Kansas City, KS. Wednesday, October 3, 2018.
87. **Moriarty PM**. Update on the Treatment of Atherosclerosis and Cardiovascular Disease. Southwest Clinical Society Conference. Overland Park, KS. Thursday, October 4, 2018.
88. **Moriarty PM**. An Update on Lp(a). KUMC Department of Cardiovascular Medicine Grand Rounds. Kansas City, KS. Tuesday, February 26, 2019.
89. **Moriarty PM**. Update on the Treatment of Dyslipidemia. Kansas ACC 6th Annual Cardiovascular Symposium. Overland Park, KS. Saturday, October 5, 2019.
90. **Moriarty PM**. Updates in Lp(a). Cardiometabolic Health Congress. Chicago, IL. Saturday, October 12, 2019.
91. **Moriarty PM**. North American Lipoprotein Apheresis Registry (NALAR): Data Collection design and rationale. International Society for Apheresis Congress. Kyoto, Japan. October 18, 2019.
92. **Moriarty PM**. Antisense and RNA interference drug therapy for the reduction of Lp(a) levels. International Society for Apheresis Congress. Kyoto, Japan. October 19, 2019.
93. **Moriarty PM**, Thompson PD, Underberg JA. PCSK9 Inhibitors in Practice: Real-World Strategies for Cardiovascular Risk Reduction. Horizon CME. Kansas City, MO. November 12, 2019.
94. **Moriarty PM**. Management Strategies for Patients with Familial Hypercholesterolemia. Cardiovascular Medicine Grand Rounds. Kansas City, KS. December 11, 2019.
95. **Moriarty PM**. Updates on Treatment of Atherosclerosis & CV. Cardiovascular Medicine Grand Rounds. Kansas City, KS. January 8, 2020.
96. **Moriarty PM**. Update on Lipoprotein(a). Cardiovascular Medicine Grand Rounds Ohio State Medical Center. September 18, 2020.
97. **Moriarty PM**. Focus on Lp(a)  $\geq$  60 mg/dl & LDL-C  $\geq$  100 mg/dl with either established CAD or PAD and in combination with diet & maximum tolerable lipid-lowering drug therapies that failed to achieve the recommended therapeutic targets. NLA Lipid Palooza with Dr. Mary McGowan. September 18, 2020.

98. **Moriarty PM**. Lipoprotein Apheresis and Inflammation. UC San Diego Health. October 27, 2020.
99. **Moriarty PM**. FDA Approval for Lipoprotein Apheresis. Cardiology Grand Rounds Albert Einstein College of Medicine. Bronx, NY November 10, 2020.
100. **Moriarty PM**. RDW Discussion with Michael Louie. February 12, 2021.
101. **Moriarty PM**. New Frontiers of FH Care. FH Global Summit. February 17, 2021.
102. **Moriarty PM** Update on Present and Future Lipid Modifying Therapy. Virtual Emirates Diabetes& Endocrine Congress. March 6, 2021.
103. **Moriarty PM** Chair Session: Lipoprotein Apheresis. International Society for Apheresis Congress. March 17, 2021
104. **Moriarty PM** COVID-19: Does Lipid-apheresis add clinical benefit to the patient? International Society for Apheresis. March 19, 2021.
105. **Moriarty PM** Future of Lipoprotein Apheresis. International Society for Apheresis. March 20, 2021.
106. **Moriarty PM** What Additional Investigations are required Coagulation? Fibrinolysis?, APOE?, Others?. International Society for Apheresis. March 20, 2021.
107. **Moriarty PM** Help your Recent MI Patients achieve Lower LDL and Reduce the Risk of Another MI. Kansas City, MO. March 24, 2021.
108. **Moriarty PM** LDL & Lp(a) are Independent and Additive Contributors to Atherosclerotic Cardiovascular Disease. Virtual Presentation (Kaneka). April 15, 2021.
109. **Moriarty PM** New Drug. KC Cardiologist. April 28, 2021.
110. **Moriarty PM** Innovations in Low-density Lipoprotein (LDL) Apheresis: Reviewing Theory, Practical Applications, & Future State. American Society for Apheresis. May 13, 2021.

### **PRESENTATIONS: Conference Posters & Abstracts**

1. **Moriarty PM**. Neutropenia induced from chronic metoclopramide. Kansas Association of Internal Medicine, Kansas City, KS, 1992.

2. **Moriarty PM**. Eosinophil fasciitis as a graph vs. host disease from an autologous bone marrow transplant. Kansas Association of Internal Medicine, Kansas City, KS, 1993.
3. **Moriarty PM**. Relative risk reduction vs. number needed to treat as measures of lipid trials results. XI International Symposium on Atherosclerosis, Paris, 1998.
4. **Moriarty PM**. Dyslipidemia and cardiovascular disease: Significance of treatment. 5th International Symposium on Multiple Risk Factors in Cardiovascular Disease: Global Assessment and Intervention, Venice, Italy, 1999.
5. Sullivan D, Gibson C, **Moriarty PM**, Holcomb S, Paolo A, Calkins D. Adherence to clinical guidelines for obesity by internal medicine residents. National Association for the Study of Obesity (NAASO) Annual Conference, Long Beach, CA, October 29 – November 3, 2000.
6. Samad S, Welch K, **Moriarty PM**, Gustafson J, Lindsley C, & Stechschulte D. Use of ultrasonographic imaging (USI) to evaluate and monitor skin thickness. American College of Physicians-ASIM 2000 Kansas Chapter Scientific Meeting, Kansas City, MO, Sep 8 - 9, 2000.
7. **Moriarty PM**, Gibson, CA, Kensey, KR, Hogennauer, WN, LDL Apheresis and its Effect on Whole Blood Viscosity. American College of Cardiology Annual Scientific Sessions, March 17-20, 2001.
8. Backes J, **Moriarty PM**, Gibson C. “The Effects of Micronized Fenofibrate on Lipid Profiles of Patients Converted from Gemfibrozil.” American College of Cardiology, 50th Annual Scientific Session, Orlando, FL, March 18-21, 2001
9. **Moriarty PM**, Gibson C, Shih J. HELP LDL-Apheresis and its effect on C-Reactive Protein. American Heart Association, 2nd Annual Conference of Arteriosclerosis, Thrombosis and Vascular Biology, Arlington, VA, May 11-13, 2001.
10. Samad AS, Welch KE, **Moriarty PM**, Gustafson J, Lindsley CB, Stechschulte DJ. Measurement of changes in skin thickness with ultrasonographic imaging (USI). American College Rheumatology 65th Annual Scientific Meeting.
11. Gibson CA, Moranetz CA, Schmelzle KH, Featherston WL, **Moriarty PM**, Dismuke SE. Exercise patterns, BMI, dietary habits, and cholesterol levels among first-year medical students: A five-year examination of health behaviors. NAASO (North American Association for the Study of Obesity) 2001 – Annual Meeting October 7-10, 2001, Quebec City.

12. **Moriarty PM**, Gibson CA, Kensey KR, Hogenauer WN. HELP LDL Apheresis and Its Effect on Whole Blood Viscosity. Third Annual Conference on Arteriosclerosis, Thrombosis, and Vascular Biology, Salt Lake City, Utah, April 6-8, 2002.
13. **Moriarty PM**, Gibson CA, Kim N, Wolfert RL. HELP LDL Apheresis and Its Effect on Lipoprotein-Associated Phospholipase A2. Third Annual Conference on Arteriosclerosis, Thrombosis, and Vascular Biology, Salt Lake City, Utah, April 6-8, 2002.
14. **Moriarty PM**, Owens SD, Vacek JL, Gibson CA, Mayo MS, Tadros P, Delafontaine P. The HELPME Trial: A Study to Demonstrate the Utility of HELP LDL-Apheresis Treatment for Patients with Acute Unstable Angina or Non-Q-Wave Myocardial Infarction. Giovanni Lorenzini Medical Foundation. Florence, Italy, June 12-15, 2002.
15. **Moriarty PM**, Gibson CA, Flechsenhar K, Mayo M.S., Vacek J.L., Tadros, P, Owens, S.D., Delafontaine P. A Study to Demonstrate the Utility of HELP LDL Apheresis Treatment for Patients with Non-ST Elevation Acute Coronary Syndrome. European Atherosclerosis Society, Salzburg, Austria, July 7- 10, 2002.
16. **Moriarty PM**, Gibson CA, Kensey KR, Hogenauer WN "LDL Apheresis and Its Effect on Whole Blood Viscosity". American Society for Apheresis Journal of Clinical Apheresis, Vol. 18 #2, 2003 pp. 81.
17. Gibson C, Paolo A, **Moriarty PM**. Cognitive and Emotional Functions After Rapid Cholesterol Lowering. Annual Convention of the American Psychological Association, Toronto, Canada, August 7-10, 2003.
18. **Moriarty PM**. Atherosclerosis and Rheology: which comes first the chicken or the egg? 13th Conference of the European Society for Clinical Hemorheology (E.S.C.H.), Siena, Italy, 2005.
19. **Moriarty PM**. Atherosclerosis and Rheology: which comes first the chicken or the egg? Hemorheopheresis session of the 5th International Society for Apheresis, Rostock/Warnemuende, Germany, 2005.
20. **Moriarty PM**. Blood Viscosity: A Marker of Asymptomatic Vascular Disease in Children. AHA 46th Annual conference on Cardiovascular Disease Epidemiology and Prevention in association with the Council of Nutrition, Physical Activity, and Metabolism, Phoenix, Arizona, March 2006.
21. **Moriarty PM**, Opole IO, Kumar A, Belmont JM. Reduction of Inflammatory HDL Following LDL-apheresis Treatment. American Heart Association and presented as a poster at ISA06 XIV International Symposium on Atherosclerosis, Rome, Italy,

June, 2006

22. Backes J, **Moriarty PM**, Gons A, Gibson C, Hanson N , Ruisinger J. Statin therapy effective and better tolerated when administered every other day among patients with previous adverse effects. American College of Clinical Pharmacy Annual Meeting, St. Louis, MO, October 27, 2006.
23. **Moriarty PM**, Le N, Dutton J, Brown WV. Acute Changes in Oxidative and Inflammatory Markers with LDL-Apheresis. American Heart Association 2006 Scientific Session, Chicago, IL, November 13, 2006.
24. **Moriarty PM**. Advances in LDL-apheresis. 6th World Congress of the International Society for Apheresis and World Apheresis Association 11th Congress, Yokohama, Japan, March 4, 2007.
25. **Moriarty PM**. Once Weekly Dose of Rosuvastatin for Patients with Prior Statin Intolerance. 2007 XVI International Symposium on Drugs Affecting Lipid Metabolism (DALM ), New York, NY, October 4, 2007.
26. **Moriarty PM**. Update: The Primary Care Prevention of Vascular Disease. Preventive Cardiology in Primary Care, Topeka, KS, October 19, 2007.
27. Backes JM, Gibson CA, Ruisinger JF, **Moriarty PM**. Once Weekly Statin Therapy Effective and Well-Tolerated in Patients with a Prior Statin Intolerance. American College of Clinical Pharmacy spring Meeting, Phoenix, AZ, April 7, 2008.
28. Backes JM, Ruisinger, JF, Gibson CA, **Moriarty PM**. Effects of Policosanol when used in a lipid-specialty clinic. American college of Clinical Pharmacy Spring Meeting, Phoenix, AZ, April 8, 2008.
29. **Moriarty PM**. LDL-Apheresis and the Acute Reduction of Inflammatory HDL-C. 14th World Congress on Heart Disease, The International Academy of Cardiology Annual Scientific Sessions 2008, Toronto, ON, Canada, July 28, 2008.
30. **Moriarty PM**, Barnes BJ, Ruisinger JF, Backes JM. Assessment of Accelerated Atherosclerosis in Asymptomatic Firemen: The 4 “A”larm Study. 49th Cardiovascular Disease Epidemiology and Prevention Annual Conference, and Nutrition, Physical Activity and Metabolism Conference, Palm Harbor, Florida, March 12, 2009.
31. **Moriarty PM**. Apolipoprotein E4 and Its Reduction Following LDL-Apheresis. XV International Symposium on Atherosclerosis, John B. Hynes Convention Center, Boston, Massachusetts, June 17, 2009.

32. Bulchandani D, **Moriarty PM**. Acute Reduction of Lipoprotein(a) After Low-Density Lipoprotein Apheresis May Improve Symptoms of Angina. 2010 National Lipid Association Scientific Sessions. Sheraton Hotel and Towers, Chicago, Illinois, May 15, 2010.
33. **Moriarty PM**, Luyendyk JP, Gibson CA, Backes JM. Effect of Low Density Lipoprotein Apheresis on Plasma Levels of Apolipoprotein E4. International Academy of Cardiology 15th World Congress on Heart Disease Annual Scientific Sessions 2010, Vancouver, BC, Canada, July 26, 2010.
34. Eldringhoff DM, Backes JM, Ruisinger JF, Dutton JS, Barnes BJ, Belmont JM, **Moriarty PM**. Aggressive treatment of cardiovascular risk factors results in the reduction of atherosclerosis growth as measured by carotid intima media thickness: experience from an atherosclerosis prevention clinic. International Academy of Cardiology, 15th World Congress on Heart Disease Annual Scientific Sessions 2010, Vancouver, BC, Canada, July 26, 2010.
35. Bulchandani D, **Moriarty PM**. Acute Reduction of Lipoprotein(a) After Low-Density Lipoprotein Apheresis May Improve Symptoms of Angina. International Academy of Cardiology 15th World Congress on Heart Disease Annual Scientific Sessions 2010, Vancouver, BC, Canada, July 27, 2010.
36. Saad AF, **Moriarty PM**. “LDL-apheresis for Prevention of Recurrent Hypertriglyceridemia-Induced Acute Pancreatitis, A Case Report.” National Lipid Association Scientific Session, New York, New York, May 20, 2011.
37. **Moriarty PM**, Gibson CA, Backes JM, Eldringhoff DM, Powell S, Ruisinger JF. “The Effect of Aggressive Cardiovascular Treatment on the Progression of Carotid Intima-Media Thickness: Experience of an Atherosclerosis Prevention Center”. 79th European Atherosclerosis Society Congress, Gothenburg, Sweden, June 26, 2011.
38. Saad AF, **Moriarty PM**. “LDL-apheresis for Prevention of Recurrent Hypertriglyceridemia-Induced Acute Pancreatitis, A Case Report.” 79th European Atherosclerosis Society Congress, Gothenburg, Sweden, June 26, 2011.
39. **Moriarty PM**. “Beyond Statins: LDL Management in the Challenging Patient”. ACC 61<sup>st</sup> Annual Scientific Session ACC-i2 with TCT, Chicago, Illinois, March 24-27, 2012.
40. **Moriarty PM**, Heckerson N. “Resolution of recurrent postoperative pericarditis after lipid apheresis: a case report.” Journal of Clinical Lipidology (2012), 6(3), 271.

41. Wilson, M, Gibson C, Powell S, Eldringhoff D, Backes J, **Moriarty PM**. “The Effect Of Aggressive Cardiovascular Treatment On The Progression Of Carotid Intima-Media Thickness: Experience Of An Atherosclerosis Prevention Center”. June 1st, 2012, Scottsdale, AZ
42. **Moriarty PM**, Backes JM, Ruisinger JF, Schmelzle K, Dutton JA, He W. “Apple-pectin and its ability to reduce niacin-induced flushing”. The European Atherosclerosis Society Congress, May 26-27, 2012, Milan, Italy
43. Schuessler B, Ruisinger JF, **Moriarty PM**, Backes JM. “Evaluating vitamin D dosing in obese patients with low vitamin D levels”. The Midwest Pharmacy Residents Conference, May 10-11, 2012, Omaha, NE
44. Backes JM, Padley R, Ruisinger JF, Acree LS, Luoma JT, **Moriarty PM**. “Dietary supplement versus prescription niacin products: Differentiation and important considerations for use in patients with dyslipidemia”. The American Pharmacist Association Annual Meeting, March 9-12, 2012, New Orleans, LA
45. Schuessler B, Ruisinger JF, Grauer, DW, **Moriarty PM**, Backes JM. “Comparison of vitamin D dosing regimens in non-obese and obese patients with low vitamin d levels”. The American College of Clinical Pharmacy Annual Meeting, October 22nd, 2012, Hollywood, FL
46. Backes JM, Ruisinger JF, Gibson CA, Varvel S, **Moriarty PM**. “The High-Dose Rosuvastatin Once Weekly Study (HDROWS) – The Effects on Advanced Lipid, Glycemic, and Inflammatory Panels”. The American College of Clinical Pharmacy Annual Meeting, October 15th, 2013, Albuquerque, NM
47. Ruisinger JF, Backes JM, Harris KA, Gibson CA, Harris WS, **Moriarty PM**. “Evaluating the Effects of Krill Oil, Supplemental Fish Oil, and Prescription Fish Oil on Lipoproteins and Gastrointestinal Symptoms – A Randomized Controlled Trial. The American College of Clinical Pharmacy Annual Meeting, October 15th, 2013, Albuquerque, NM
48. Gilroy R, Heronemus M, Schmitt T, **Moriarty PM**. Donors with Familial Hypercholesterolemia and clinical outcome in liver transplant recipients. 2014;98:796.
49. Sehar N, **Moriarty PM**. “Impact Of Lipoprotein Apheresis on Serum Myeloperoxidase Levels in Patients with Familial Hypercholesterolemia”. European Atherosclerosis Society. March 2015. Glasgow, Scotland.
50. Anabtawi A, Patel P, Deuschele L, **Moriarty PM**. “Long Term Follow up of Bi-Weekly Lipoprotein Apheresis in A patient with Elevated Lipoprotein-(a) Shows Regression in Carotid Intima-Media Thickness” National Lipid Association. June

2015. Chicago, Illinois.

51. **Moriarty PM**, Badawi AH, Lepping RJ, Nolte B, Tye SL, Bishara M, Burns J, Brooks WM. “EECP Therapy for Patients with Mild Cognitive Impairment” Accepted for poster at the International Conference on Heart and Brain. February 25, 2016.
52. **Moriarty PM**, Thiessen ES, Viney NJ, Witztum JL, Tsimikas S. “Rationale and design of a clinical trial to assess Lp(a) lowering with IONIS-APO(a)-LRx in patients undergoing apheresis for elevated Lp(a) and recurrent cardiovascular events” Accepted for poster at the European Atherosclerosis Society 2016 (May 29- June 1, 2016)
53. **Moriarty PM**, Parhofer KG, Babirak SP, et al. “The ODYSSEY ESCAPE Study: rationale, design, patient characteristics at baseline, and final study data” Accepted for presentation at the European Society of Cardiology 2016 (August 27– August 31, 2016)
54. Roth WM, **Moriarty PM**, Bergeron J, et al. “A Phase 3 Randomized Trial Evaluating Alirocumab 300 mg Every 4 Weeks as Monotherapy or Add-On to Statin: ODYSSEY CHOICE I” Accepted for presentation at the National Lipid Association 2016 (May 19–May 22, 2016).
55. **Moriarty PM**, Sehar N, Denney LK, Perez-Marques F, Panchal A, Luna P. “Elevated Lipoprotein(A) And Ischemic Strokes- A Case Report” Accepted for poster at the European Atherosclerosis Society 2016 (May 29 – June 1, 2016)
56. Haikal A, Sehar N, Denney LK, **Moriarty PM**. “Adult Relapsing Focal Segmental Glomerulosclerosis (FSGS) Maintained In Partial Remission Following Lipoprotein Apheresis: Case Study” Accepted for Poster at the European Atherosclerosis Society 2016 (May 29 - June 1, 2016)
57. **Moriarty PM** et al. “Pitavastatin Lowers Plasma Levels of CoQ10 less than Equipotent Doses of Rosuvastatin or Atorvastatin. Symposium of the International Atherosclerosis Society. St. Petersburg, Russia. June 3, 2016.
58. Roth EM, **Moriarty PM**, Bergeron J, Langslet, Manvelian G, Zhao J, Baccara-Dinet MT, Rader DJ. “Efficacy and safety of the PCSK9 inhibitor alirocumab 300 mg every 4 weeks in patients with ASCVD” Submitted for European Atherosclerosis Society 2017 (April 23 – 26, 2017)
59. Guerra P, Dunn F, **Moriarty PM**, Bergeron J, Langelet G, Manvellan G, Zhao J, Baccara-Dinet MT, Roth EM. Efficacy and Safety of the PCSK9 Inhibitor Alirocumab 300 mg Every 4 Weeks in Patients with ASCVD. AAPA 2017.

60. **Moriarty PM**, Barirak SP, Cornier MA et al. Effect of Apheresis on Alirocumab and PCSK9 Concentrations in the ODYSSEY ESCAPE Study. Submitted for American Heart Association 2017 (November 11 – 15, 2017)
61. **Moriarty PM**, Dunbar RL, Hemphill L, Babirak SP, Wilson G, Iydroose M, Tennant H, Dacus K, Goldberg AC. ESCAPE to the real world: a retrospective review of clinical use of Alirocumab in lipoprotein apheresis patients. Submitted to 12th International Congress on Innovations in Coronary Artery Disease (ICCAD 2017).
62. Heidl R, **Moriarty PM**, Sperling L, Tennant H, Ricketts J. Lipoprotein X Disease in the Setting of Severe Cholestatic Hepatobiliary Autoimmune Disease. *Clinical Cardiology*. 2017;40(Suppl. 1):4-15. 2017 ASPC Congress on Cardiovascular Disease Prevention.
63. **Moriarty PM**, Yeang C, Varvel SA, McConnell JP, Tsimikas S. Removing the Lipoprotein (a)-Cholesterol From the LDL-C Measurement Results in a 38% Reduction in Prevalence of Elevated LDL-C at Any Threshold: Implications for the Prevalence and Diagnosis of LDL-Mediated Risk. Submitted and presented at the American College of Cardiology Scientific Sessions 2018 (March 10, 2018).
64. Minchew HM, Okonta DC, **Moriarty PM**. Treating Lipoprotein(a)-hyperproteinemia and Progressive Cardiovascular Disease with Lipid-Apheresis in North America. Submitted and presented at the American College of Cardiology Scientific Sessions 2018 (March 10, 2018).
65. Bittner VA, Szarek M, Aylward PE, Bhatt DL, Diaz R, Fras Z, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Loizeau V, **Moriarty PM**, Moryusef A, Pordy R, Roe MT, Sinnaeve P, Vogel R, White HD, Zahger D, Zeiher A, Steg PG, Schwartz GG, for the ODYSSEY OUTCOMES Investigators “The Odyssey Outcomes Trial: Lp(a) and Cardiovascular Disease Outcomes” Presented at the 2018 International Atherosclerosis Society Symposium (June 12,2018).
66. **Moriarty PM**. Vaisar T. Dutton JA, Denney LK, Hippe D, Heinecke JW, Zhao X-Q. The change in HDL proteomics following lipid-apheresis therapy. Presented at the European Society of Cardiology. Munich, Germany. Tuesday, August 28, 2018.
67. **Moriarty PM**, Thompson PD, Cannon CP, Guyton JR, Bergeron J, Zieve FJ, Bruckert E, Jacobson TA, Baccara-Dinet MT, Zhao J, Donahue S, Ali S, Pordy R, Gipe DA. Efficacy and safety of alirocumab in statin-intolerant patients over 3 years: Open-label extension of the ODYSSEY ALTERNATIVE trial. Poster at the American Heart Association Scientific Sessions 2018 (November 11, 2018).
68. Tsimikas S, Karwatowska-Prokopczuk E, Gouni-Berthold I...**Moriarty PM** et al. Safety and Efficacy of AKCEA-APO(a)-LRx to Lower Lipoprotein(a) Levels in

Patients With Established Cardiovascular Disease: A Phase 2 Dose-Ranging Trial. Presented at the American Heart Association Scientific Sessions (November 10, 2018).

69. Cuchel M, Knowles JW, Kindt Iris...**Moriarty PM** et al. Homozygous Familial Hypercholesterolemia in the United States: Data From the CASCADE-FH Registry. Presented at the American Heart Association Scientific Sessions (November 12, 2018).
70. Minchew HM, Okonta DC, **Moriarty PM**. Treating Lipoprotein(a)-hyperproteinemia and Progressive Cardiovascular Disease with Lipid-Apheresis in North America. Presented at the KUMC Internal Medicine Research Day. (March 5, 2019).
71. **Moriarty PM**. Vaisar T. Dutton JA, Denney LK, Hippe D, Heinecke JW, Zhao X-Q. The change in HDL proteomics following lipid-apheresis therapy. Presented at KUMC Internal Medicine Research Day. (March 5, 2019).
72. **Moriarty PM**, Badawi AH, Lepping RJ et al. “EECP Therapy for Patients with Mild Cognitive Impairment” Presented at KUMC Internal Medicine Research Day. (March 5, 2019).
73. Bittner V, Szarek M, Aylward P, Bhatt DL, Diaz R, Edelberg JM, Frasz Z, Goodman S, Halvorsen S, Hanotin C, Harrington RA, Jukema JW, Loizeau V, **Moriarty PM**, Moryusef A, Pordy R, Roe MT, Sinnaeve P, Tsimikas S, Vogel R, White HD, Zahger D, Zeiher AM, Steg PG, Schwartz GG. Lipoprotein(a) Lowering by Alirocumab Contributes to Total Events Reduction Independent of Low-Density Lipoprotein Cholesterol in the ODYSSEY OUTCOMES Trial. Presented at the American College of Cardiology Scientific Sessions (March 18, 2019).
74. Roe MT, Szarek M, Li QH, Bhatt DL, Bittner V, Goodman SG, Harrington RA, Lopez-Jaramillo P, Lopes RD, Louie MJ, **Moriarty PM**, Vogel RA, Baccara-Dinet MT, Steg PG, Schwartz GG. Efficacy of alirocumab treatment after acute coronary syndrome according to new ACC/AHA guidelines for lipid-lowering therapy. Presented at the European Society of Cardiology Congress (September 2, 2019).
75. Brooks W, Burns J, Eckland-Johnson E, Gorby L, Helfgott J, Lepping R, **Moriarty PM**, Salat D. Treatment of Mild Cognitive Impairment Due to Alzheimer’s Type: Design and Rationale of the Randomized Pivotal Study of Review. Presented at the Alzheimer’s Association International Conference. Los Angeles CA. (July 17, 2019).
76. Alexander E, **Moriarty PM**. Establishing Low-Density Lipoprotein Apheresis Tolerability in Patients with Prior Anaphylactoid Reactions to Lipid Apheresis

using Magnesium Sulfate. International Society for Apheresis Congress. Kyoto, Japan. October 18, 2019.

77. **Moriarty PM**, Gorby L, Zeiher AM et al. Relation of Red Blood Cell Distribution Width to Risk of Major Adverse Cardiovascular Events, Death, and Effect of Alirocumab After Acute Coronary Syndrome. American Heart Association Scientific Sessions. Philadelphia, PA. November 16, 2019.
78. Holyoak MD, Gorby LK, **Moriarty PM**. PCSK9 Inhibitors, An Ineffectual Treatment For Apolipoprotein B-100 Defective Familial Hypercholesterolemia. American Heart Association Scientific Sessions. Philadelphia, PA. November 16, 2019.
79. **Moriarty PM**, Dutton JA, Gorby L, Vance J, Ali S, Zhao A, Khilla N, Alejandro M, Rodriguez J, Rajadhyaksha M, Andisik M, Gipe DA, Zhang Y. Evaluating the effect of lipid on Evinacumab and angiopoietin-like 3 levels. Virtual European Atherosclerosis Society Congress. October 5, 2020.
80. Zahger D, Szarek M, Bhatt DL, Bittner VA, Budaj A, Diaz R, Goodman SG, Jukema JW, Kiss RG, McGinniss J, Harrington RA, **Moriarty, PM**, Steg PG. Triglyceride Levels and Cardiovascular Outcomes After Acute Coronary Syndrome: Insights From the Odyssey Outcomes Trial. Circulation. 2020 Nov 17;142(Suppl\_3):A15281-.
81. Koren MJ, **Moriarty PM**, Neutel J, Baum SJ, Hernandez-Illas M, Weintraub HS, Hellawell J, Varrieur T, Sohn W, Wang H, Elliott-Davey M. safety, tolerability and efficacy of single-dose Amg 890, a novel Sirna targeting Lp (a), in healthy subjects and subjects with elevated Lp (a). Circulation. 2020 Nov 17;142(Suppl\_3):A13951.
82. Hadley T, Agha A, Pulipati VP, Brummel K, Rearick C, Nugent A, Roth M, **Moriarty PM**, Davidson M, Ballantyne C. GENETIC TESTING FOR HYPERTRIGLYCERIDEMIA-A MULTI-CENTER STUDY. Journal of the American College of Cardiology. 2021 May 11;77(18\_Supplement\_1):1472.
83. Rosenson RS, Gaudet D, Ballantyne CM, Baum SJ, Bergeron J, Kershaw EE, **Moriarty PM**, Rubba P, Whitcomb DC, Banerjee P, Gewitz A, McGinnis J, Ponda MP, Pordy R, Zhao J, Rader DJ. A Phase 2 Trial of the Efficacy and Safety of Evinacumab in Patients with Severe Hypertriglyceridemia. Virtual European Atherosclerosis Society. June 1, 2021.
84. Rosenson RS, Gaudet D, Ballantyne CM, Baum SJ, Bergeron J, Kershaw EE, **Moriarty PM**, Rubba P, Banerjee P, Ponda MP, Pordy R. A phase 2 trial of the efficacy and safety of Evinacumab in patients with severe hypertriglyceridemia. Atherosclerosis. 2021 Aug 1;331:e293.

85. Safarova MS, Gorby L, Nugent A, Dutton JA, **Moriarty PM**. Vascular Age in Patients With Familial Hypercholesterolemia and/or Elevated Lipoprotein (a) Treated With Lipoprotein Apheresis. *Circulation*. 2021 Nov 16;144(Suppl\_1):A9055-.
86. **Moriarty PM**, Gorby LK, Salat DH, Burns JM, Moreno TN, Helfgott J. Cerezen (Renew™ NCP-5) for the Treatment of Mild Cognitive Impairment due to Alzheimer’s Disease or Mild Dementia of the Alzheimer’s Type in Subjects With Type 2 Diabetes. 2022 May (P5-3.001).
87. Yeang C, Nugent A, Su F, Dinh B, Tsimikas S, **Moriarty PM**. LDL-C Corrected for Directly Measured Lipoprotein (a)-Cholesterol in Patients Treated with Lipoprotein Apheresis. *Journal of the American College of Cardiology*. 2022 Mar 8;79(9\_Supplement):1045-.
88. **Moriarty PM**, Gorby L, Safarova M, Salat D, Burns J, Moreno T, et al. External Counterpulsation on performance in patients with mild cognitive impairment or mild Alzheimer’s Disease: A randomized sham-controlled study. *J Am Coll Cardiol*. 2023;81(8):1642.
89. Kronenberg F, Mora S, Stroes ESG, Ference BA, Arsenault BJ, Berglund L, Dweck MR, Koschinsky ML, Lambert G, Mach Franç, McNeal CJ, **Moriarty PM**, Natarajan P, Nordestgaard BøG, Parhofer KG, Virani SS, von Eckardstein A, Watts GF, Stock JK, Ray KK, Tokgözoğlu LS, Catapano AL, From the EAS:\* frequent questions and responses on the 2022 lipoprotein(a) consensus statement of the European Atherosclerosis Society, *Atherosclerosis* (2023).
90. Frederick J. Raal, Robert S. Rosenson, **Moriarty PM**, Shazia Ali, Poulabi Banerjee, Jian Zhao, Richard T. George, Jennifer McGinniss, Robert Pordy. Evinacumab reduces US apheresis eligibility in patients with homozygous familial hypercholesterolemia. 2023 Jun 1.
91. **Moriarty PM**, McClellan MW, Tabak CA. Lipoprotein-Apheresis Therapy for Patients with an Elevated Lipoprotein(a), and Progressive Cardiovascular Diseases, Reduces the Development of Calcific Aortic Valve Stenosis. 2023 Jun 3
92. **Moriarty PM**, Safarova M, McClellan MW, Dutton J. Lipoprotein Apheresis improves HDL Proteomics and reduces the risk of Aortic Valve Stenosis in Patients with Elevated Lp(a) Levels. 2025 Jan 15.

**SPEAKER, CONSULTANT, ADVISORY, & SCIENTIFIC BOARD AFFILIATIONS**

- 2019- Novartis Pharmaceuticals Advisory Board
- 2018- Amgen Scientific Speaker
- 2018- Medicine Company Advisory Board

**2017-** Stage II Innovations Consultant  
**2018-** Amarin Pharmaceuticals Speaker  
**2015-** Kaneka Corporation Consultant  
**2012-** Sanofi Pharmaceuticals Speaker Bureau member & Consultant  
**2012-** Regeneron Pharmaceuticals Consultant & Speaker  
**2016-** Lilly Executive Committee  
**2015-** Esperion Executive Committee  
**2014-** Midwest Lipid Association  
**2014-** Medical Advisory Board for FH Foundation  
**2014-** Medical Advisory Board for Lp(a) Foundation  
**2012-** FH Scientific Advisory Board  
**2012** President of International Society for Apheresis  
**2012-** Scientific Advisory Board for International Society for Apheresis  
**2011-** Scientific Advisory Board (MIPO03801011 Study)  
**2006** Recertification, Diplomat, American Board of Internal Medicine  
**2005-** National Lipid Association Speaker  
**2000** Merck Pharmaceuticals Consultant  
**1998** Educational Commission for Foreign Medical Graduates